[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fadLdRJkF99FAJjyvq5kbtCRLIvgy7KY0TSubMQO1eVk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"McGill University",[4,6],"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",650,false,137,49,203321,50,477,[15,18,21,24,27,30,32,35],{"name":16,"count":17},"Stroke",15,{"name":19,"count":20},"Type 1 Diabetes",14,{"name":22,"count":23},"Diabetes Mellitus, Type 1",13,{"name":25,"count":26},"Healthy",10,{"name":28,"count":29},"HIV Infections",8,{"name":31,"count":29},"Chronic Obstructive Pulmonary Disease",{"name":33,"count":34},"Obesity",7,{"name":36,"count":34},"HIV",[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02780024","Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM","2021-10-20","Metformin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04169191","Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia","2021-12-31","Sildenafil Citrate",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06021145","Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes","2025-05","Empagliflozin",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT07142486","Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal","2026-03","Omeprazole 20 mg",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05309785","Safety and Efficacy of Canagliflozin in Advanced CKD","2026-03-30","Invokana 300 mg and 100 mg",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06375304","The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study","2026-06-01","B\u002FF\u002FTAF",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07249827","A Randomized Comparison Between 0.67 mcg\u002Fkg, 1 mcg\u002Fkg, and 1.33 mcg\u002Fkg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block","2026-06-30","dexmedetomidine (perineural) 0.67 mcg\u002Fkg",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06126419","Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration","2026-07","High-Dose Insulin Therapy",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT07069582","Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women","2026-10-31","Standard dose rifampicin",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT04249154","Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer","2026-12-15","Eligard",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,141,176,194,212,236,269,287,305,323,343,363,391,409,435,499,521,563,602,620,638,663,692,710,737,764,782,800,818,843,864,899,917,935,953,979,1005,1023,1041,1086,1114,1132,1150,1168,1186,1204,1230,1252,1286,1310,1331,1367,1396,1422,1440,1458,1482,1508,1526,1552,1577,1604,1631,1659,1677,1695,1719,1744,1770,1795,1821,1839,1864,1887,1913,1931,1958,1986,2004,2029,2056,2074,2100,2136,2158,2194,2216,2244,2266,2290,2315,2340,2365,2391,2409,2438,2456,2480,2506,2529,2552,2578,2607,2625,2650,2677,2701,2726,2753,2771,2789,2811,2837,2862,2880,2905,2928,2952,2978,2996,3020,3038,3062,3088,3112,3136,3161,3185,3212,3230,3253,3275,3299,3323,3345,3370,3396,3420,3443,3466,3492,3510,3528,3546,3564,3588,3606,3624,3646,3670,3688,3713,3731,3758,3776,3794,3812,3837,3864,3887,3910,3935,3960,3978,4000,4025,4049,4072,4096,4119,4142,4194,4232,4266,4288,4310,4341,4368,4390,4414,4439,4464,4488,4514,4532,4556,4578,4600,4618,4636,4664,4682,4705,4730,4748,4766,4794,4812,4838,4856,4881,4902,4924,4947,4973,4991,5016,5042,5060,5083,5101,5128,5146,5169,5192,5216,5238,5256,5278,5301,5319,5341,5367,5395,5413,5438,5456,5484,5502,5520],{"intervention":97,"totalTrials":98,"cells":99},"acetaminophen",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":121,"NA":139},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":102},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT05246644","IV Acetaminophen After Cardiac Surgery - PILOT","UNKNOWN",[92],"2024-09-30","2024-12-15","2023-06-06",900,[119],"Delirium",[97],{"trials":122,"activeCount":138,"soonestReadout":128},[123],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":137},"NCT06613178","Intravenous Acetaminophen After Cardiac Surgery - Definitive Study","RECRUITING",[93],"2027-07-01","2027-12-15","2024-07-02",1100,[133,134,135,136],"Post Operative Delirium","Post Operative Pain","Post-Op Complication","Post-cardiac Surgery",[97],1,{"trials":140,"activeCount":102},[],{"intervention":142,"totalTrials":138,"cells":143},"Clindamycin + primaquine",{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":174},{"trials":145,"activeCount":102},[],{"trials":147,"activeCount":102},[],{"trials":149,"activeCount":102},[],{"trials":151,"activeCount":102},[],{"trials":153,"activeCount":138,"soonestReadout":159},[154],{"nctId":155,"briefTitle":156,"status":157,"phases":158,"primaryCompletion":159,"completion":160,"start":56,"enrollment":161,"conditions":162,"interventions":171},"NCT07357103","Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)","NOT_YET_RECRUITING",[93],"2029-03","2029-09",416,[163,164,165,166,167,168,169,170],"Pneumocystis","Pneumocystis Infection","Pneumocystis Carinii Infection","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystis Jirovecii Pneumonia","Pneumocystis Jirovecii Infection","Pneumocystosis Associated With AIDS","Pneumocystosis; Pneumonia (Etiology)",[142,172,173],"Pentamidine","Atovaquone",{"trials":175,"activeCount":102},[],{"intervention":172,"totalTrials":138,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":192},{"trials":179,"activeCount":102},[],{"trials":181,"activeCount":102},[],{"trials":183,"activeCount":102},[],{"trials":185,"activeCount":102},[],{"trials":187,"activeCount":138,"soonestReadout":159},[188],{"nctId":155,"briefTitle":156,"status":157,"phases":189,"primaryCompletion":159,"completion":160,"start":56,"enrollment":161,"conditions":190,"interventions":191},[93],[163,164,165,166,167,168,169,170],[142,172,173],{"trials":193,"activeCount":102},[],{"intervention":173,"totalTrials":138,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":210},{"trials":197,"activeCount":102},[],{"trials":199,"activeCount":102},[],{"trials":201,"activeCount":102},[],{"trials":203,"activeCount":102},[],{"trials":205,"activeCount":138,"soonestReadout":159},[206],{"nctId":155,"briefTitle":156,"status":157,"phases":207,"primaryCompletion":159,"completion":160,"start":56,"enrollment":161,"conditions":208,"interventions":209},[93],[163,164,165,166,167,168,169,170],[142,172,173],{"trials":211,"activeCount":102},[],{"intervention":62,"totalTrials":138,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":234},{"trials":215,"activeCount":102},[],{"trials":217,"activeCount":102},[],{"trials":219,"activeCount":102},[],{"trials":221,"activeCount":102},[],{"trials":223,"activeCount":138,"soonestReadout":61},[224],{"nctId":59,"briefTitle":60,"status":225,"phases":226,"primaryCompletion":61,"completion":66,"start":227,"enrollment":228,"conditions":229,"interventions":233},"ACTIVE_NOT_RECRUITING",[93],"2022-11-24",35,[230,231,232],"ESRD","CKD Stage 4","CKD Stage 5",[62],{"trials":235,"activeCount":102},[],{"intervention":237,"totalTrials":138,"cells":238},"Dabigatran",{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":267},{"trials":240,"activeCount":102},[],{"trials":242,"activeCount":102},[],{"trials":244,"activeCount":102},[],{"trials":246,"activeCount":102},[],{"trials":248,"activeCount":138,"soonestReadout":253},[249],{"nctId":250,"briefTitle":251,"status":126,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":263},"NCT06650501","Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia",[93],"2030-01","2026-01-15",300,[257,258,259,260,261,262],"Staphylococcus Aureus Endocarditis","Staphylococcus Aureus Septicemia","Staphylococcus Aureus Bacteremia","Staphylococcus Aureus Bloodstream Infection","S. Aureus Bacteremia","S. Aureus Bloodstream Infection",[237,264,265,266],"Apixaban","edoxaban","Rivaroxaban",{"trials":268,"activeCount":102},[],{"intervention":264,"totalTrials":138,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":285},{"trials":272,"activeCount":102},[],{"trials":274,"activeCount":102},[],{"trials":276,"activeCount":102},[],{"trials":278,"activeCount":102},[],{"trials":280,"activeCount":138,"soonestReadout":253},[281],{"nctId":250,"briefTitle":251,"status":126,"phases":282,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":283,"interventions":284},[93],[257,258,259,260,261,262],[237,264,265,266],{"trials":286,"activeCount":102},[],{"intervention":265,"totalTrials":138,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":303},{"trials":290,"activeCount":102},[],{"trials":292,"activeCount":102},[],{"trials":294,"activeCount":102},[],{"trials":296,"activeCount":102},[],{"trials":298,"activeCount":138,"soonestReadout":253},[299],{"nctId":250,"briefTitle":251,"status":126,"phases":300,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":301,"interventions":302},[93],[257,258,259,260,261,262],[237,264,265,266],{"trials":304,"activeCount":102},[],{"intervention":266,"totalTrials":138,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":321},{"trials":308,"activeCount":102},[],{"trials":310,"activeCount":102},[],{"trials":312,"activeCount":102},[],{"trials":314,"activeCount":102},[],{"trials":316,"activeCount":138,"soonestReadout":253},[317],{"nctId":250,"briefTitle":251,"status":126,"phases":318,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":319,"interventions":320},[93],[257,258,259,260,261,262],[237,264,265,266],{"trials":322,"activeCount":102},[],{"intervention":67,"totalTrials":138,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":341},{"trials":326,"activeCount":102},[],{"trials":328,"activeCount":102},[],{"trials":330,"activeCount":102},[],{"trials":332,"activeCount":102},[],{"trials":334,"activeCount":138,"soonestReadout":66},[335],{"nctId":64,"briefTitle":65,"status":157,"phases":336,"primaryCompletion":66,"completion":337,"start":338,"enrollment":12,"conditions":339,"interventions":340},[93],"2027-05-01","2024-05-01",[28],[67],{"trials":342,"activeCount":102},[],{"intervention":52,"totalTrials":138,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":361},{"trials":346,"activeCount":102},[],{"trials":348,"activeCount":102},[],{"trials":350,"activeCount":102},[],{"trials":352,"activeCount":102},[],{"trials":354,"activeCount":138,"soonestReadout":51},[355],{"nctId":49,"briefTitle":50,"status":126,"phases":356,"primaryCompletion":51,"completion":51,"start":357,"enrollment":358,"conditions":359,"interventions":360},[93],"2024-04-02",46,[19],[52],{"trials":362,"activeCount":102},[],{"intervention":364,"totalTrials":138,"cells":365},"Ustekinumab 90 mg SC q8w",{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":389},{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":102},[],{"trials":371,"activeCount":102},[],{"trials":373,"activeCount":102},[],{"trials":375,"activeCount":138,"soonestReadout":380},[376],{"nctId":377,"briefTitle":378,"status":126,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":387},"NCT07303686","De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis",[93],"2027-04-15","2027-10-15","2025-10-08",115,[385,386],"Crohn Disease (CD)","Ulcerative Colitis (UC)",[364,388],"Ustekinumab 90 mg SC q12w",{"trials":390,"activeCount":102},[],{"intervention":388,"totalTrials":138,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":407},{"trials":394,"activeCount":102},[],{"trials":396,"activeCount":102},[],{"trials":398,"activeCount":102},[],{"trials":400,"activeCount":102},[],{"trials":402,"activeCount":138,"soonestReadout":380},[403],{"nctId":377,"briefTitle":378,"status":126,"phases":404,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":405,"interventions":406},[93],[385,386],[364,388],{"trials":408,"activeCount":102},[],{"intervention":410,"totalTrials":138,"cells":411},"Systemic corticosteroids",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":433},{"trials":413,"activeCount":102},[],{"trials":415,"activeCount":102},[],{"trials":417,"activeCount":102},[],{"trials":419,"activeCount":102},[],{"trials":421,"activeCount":138,"soonestReadout":426},[422],{"nctId":423,"briefTitle":424,"status":157,"phases":425,"primaryCompletion":426,"completion":427,"start":428,"enrollment":161,"conditions":429,"interventions":432},"NCT07328984","How Long Should we Give Steroids for Patients With Severe PCP",[93],"2029-03-31","2029-06","2026-01-30",[430,163,168,431,166,169,170],"Pneumocystis Pneumonia","Pneumocystis Jiroveci Pneumonia",[410],{"trials":434,"activeCount":102},[],{"intervention":436,"totalTrials":437,"cells":438},"Normal saline",4,{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":457,"PHASE4":459,"NA":486},{"trials":440,"activeCount":102},[],{"trials":442,"activeCount":102},[],{"trials":444,"activeCount":102},[445],{"nctId":446,"briefTitle":447,"status":112,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},"NCT02624089","Nebulized Analgesia for Laparoscopic Appendectomy Trial",[90,91],"2017-06","2017-07","2016-01",200,[454],"Appendicitis",[456,436],"Ropivacaine",{"trials":458,"activeCount":102},[],{"trials":460,"activeCount":138,"soonestReadout":477},[461,473],{"nctId":462,"briefTitle":463,"status":464,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT03862404","Intrapleural Bupivacaine for Ipsilateral Shoulder Pain After Thoracotomy","COMPLETED",[93],"2019-02-15","2017-07-01",42,[470],"Post Thoracic Surgery",[472,436],"Bupivacaine-epinephrine",{"nctId":474,"briefTitle":475,"status":126,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":483},"NCT07556952","Dex & Mastectomy Pain",[93],"2028-03-31","2028-06-30","2026-04-13",170,[482],"Post-Mastectomy Chronic Pain Syndrome",[484,485],"Dexamethasone","Normal Saline",{"trials":487,"activeCount":102},[488],{"nctId":489,"briefTitle":490,"status":464,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":498},"NCT03902782","Erector Spinae Plane Block Versus Intercostal for VATS",[94],"2021-06-20","2019-06-26",100,[496,497],"Lung Cancer","Lung Diseases",[472,484,436],{"intervention":484,"totalTrials":98,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":515},{"trials":502,"activeCount":102},[],{"trials":504,"activeCount":102},[],{"trials":506,"activeCount":102},[],{"trials":508,"activeCount":102},[],{"trials":510,"activeCount":138,"soonestReadout":477},[511],{"nctId":474,"briefTitle":475,"status":126,"phases":512,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":513,"interventions":514},[93],[482],[484,485],{"trials":516,"activeCount":102},[517],{"nctId":489,"briefTitle":490,"status":464,"phases":518,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":519,"interventions":520},[94],[496,497],[472,484,436],{"intervention":522,"totalTrials":98,"cells":523},"rifampin double dose",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":544,"PHASE4":559,"NA":561},{"trials":525,"activeCount":102},[],{"trials":527,"activeCount":102},[],{"trials":529,"activeCount":102},[530],{"nctId":531,"briefTitle":532,"status":464,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT03988933","2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.",[91],"2023-01-31","2024-12-31","2019-09-20",1368,[539],"Latent Tuberculosis",[541,542,543],"Rifampin double dose","Rifampin triple dose","Rifampin standard dose",{"trials":545,"activeCount":138,"soonestReadout":550},[546],{"nctId":547,"briefTitle":548,"status":126,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":556},"NCT06498414","Shorter and Safer Treatment Regimens for Latent TB",[91,92],"2027-04-01","2029-06-01","2025-06-10",1800,[555],"Tuberculosis Infection, Latent",[557,522,558],"rifampin standard arm","levofloxacin and rifapentine",{"trials":560,"activeCount":102},[],{"trials":562,"activeCount":102},[],{"intervention":564,"totalTrials":98,"cells":565},"Vancomycin",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":598,"NA":600},{"trials":567,"activeCount":102},[],{"trials":569,"activeCount":102},[],{"trials":571,"activeCount":102},[],{"trials":573,"activeCount":138,"soonestReadout":578},[574,586],{"nctId":575,"briefTitle":576,"status":126,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":584},"NCT07328971","Vancomycin Taper to Prevent Recurrent Clostridioides Difficile",[92],"2030-06-01","2030-11-01","2026-04-24",500,[583],"Clostridia Difficile Colitis",[585,564],"Fidaxomicin",{"nctId":587,"briefTitle":588,"status":464,"phases":589,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT04138706","Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection",[92],"2024-10-04","2024-11-22","2020-11-19",263,[595],"Clostridium Difficile Infection",[564,597],"Placebos",{"trials":599,"activeCount":102},[],{"trials":601,"activeCount":102},[],{"intervention":557,"totalTrials":138,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":616,"NA":618},{"trials":605,"activeCount":102},[],{"trials":607,"activeCount":102},[],{"trials":609,"activeCount":102},[],{"trials":611,"activeCount":138,"soonestReadout":550},[612],{"nctId":547,"briefTitle":548,"status":126,"phases":613,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":614,"interventions":615},[91,92],[555],[557,522,558],{"trials":617,"activeCount":102},[],{"trials":619,"activeCount":102},[],{"intervention":558,"totalTrials":138,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":634,"NA":636},{"trials":623,"activeCount":102},[],{"trials":625,"activeCount":102},[],{"trials":627,"activeCount":102},[],{"trials":629,"activeCount":138,"soonestReadout":550},[630],{"nctId":547,"briefTitle":548,"status":126,"phases":631,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":632,"interventions":633},[91,92],[555],[557,522,558],{"trials":635,"activeCount":102},[],{"trials":637,"activeCount":102},[],{"intervention":639,"totalTrials":138,"cells":640},"Semaglutide with 4 meal strategies",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":659,"NA":661},{"trials":642,"activeCount":102},[],{"trials":644,"activeCount":102},[],{"trials":646,"activeCount":102},[],{"trials":648,"activeCount":138,"soonestReadout":653},[649],{"nctId":650,"briefTitle":651,"status":126,"phases":652,"primaryCompletion":653,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":658},"NCT06387199","Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide",[91,92],"2027-01","2024-12-01",26,[19,657],"Diabetes Mellitus",[639],{"trials":660,"activeCount":102},[],{"trials":662,"activeCount":102},[],{"intervention":664,"totalTrials":138,"cells":665},"Tirzepatide",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":688,"NA":690},{"trials":667,"activeCount":102},[],{"trials":669,"activeCount":102},[],{"trials":671,"activeCount":102},[],{"trials":673,"activeCount":138,"soonestReadout":678},[674],{"nctId":675,"briefTitle":676,"status":126,"phases":677,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":687},"NCT07284511","A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar",[91,92],"2028-01","2029-01","2026-05-19",105,[19,683,684,685,686],"Type 1 Diabetes Mellitus","T1D","T1DM","T1DM - Type 1 Diabetes Mellitus",[664],{"trials":689,"activeCount":102},[],{"trials":691,"activeCount":102},[],{"intervention":585,"totalTrials":138,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":706,"NA":708},{"trials":695,"activeCount":102},[],{"trials":697,"activeCount":102},[],{"trials":699,"activeCount":102},[],{"trials":701,"activeCount":138,"soonestReadout":578},[702],{"nctId":575,"briefTitle":576,"status":126,"phases":703,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":704,"interventions":705},[92],[583],[585,564],{"trials":707,"activeCount":102},[],{"trials":709,"activeCount":102},[],{"intervention":711,"totalTrials":138,"cells":712},"Oral Vancomycin Prophylaxis",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":719,"PHASE4":733,"NA":735},{"trials":714,"activeCount":102},[],{"trials":716,"activeCount":102},[],{"trials":718,"activeCount":102},[],{"trials":720,"activeCount":138,"soonestReadout":725},[721],{"nctId":722,"briefTitle":723,"status":126,"phases":724,"primaryCompletion":725,"completion":726,"start":727,"enrollment":255,"conditions":728,"interventions":732},"NCT06979609","Secondary Prevention of Clostridioides Difficile Using Vancomycin",[91,92],"2028-10-01","2029-10-01","2025-10-01",[729,730,731],"Clostridioides Difficile Infection","Clostridioides Difficile Infection Recurrence","Clostridoides Difficile Associated Disease",[711],{"trials":734,"activeCount":102},[],{"trials":736,"activeCount":102},[],{"intervention":738,"totalTrials":138,"cells":739},"Intervention Period 1: Semaglutide + Empagliflozin",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":760,"NA":762},{"trials":741,"activeCount":102},[],{"trials":743,"activeCount":102},[],{"trials":745,"activeCount":102},[],{"trials":747,"activeCount":138,"soonestReadout":653},[748],{"nctId":749,"briefTitle":750,"status":126,"phases":751,"primaryCompletion":653,"completion":653,"start":752,"enrollment":753,"conditions":754,"interventions":756},"NCT06894784","A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes",[92],"2025-04",36,[755],"Diabetes Type 1",[738,757,758,759],"Intervention Period 2: Semaglutide + Empagliflozin Placebo","Intervention Period 3: Semaglutide Placebo + Empagliflozin","Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo",{"trials":761,"activeCount":102},[],{"trials":763,"activeCount":102},[],{"intervention":757,"totalTrials":138,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":778,"NA":780},{"trials":767,"activeCount":102},[],{"trials":769,"activeCount":102},[],{"trials":771,"activeCount":102},[],{"trials":773,"activeCount":138,"soonestReadout":653},[774],{"nctId":749,"briefTitle":750,"status":126,"phases":775,"primaryCompletion":653,"completion":653,"start":752,"enrollment":753,"conditions":776,"interventions":777},[92],[755],[738,757,758,759],{"trials":779,"activeCount":102},[],{"trials":781,"activeCount":102},[],{"intervention":758,"totalTrials":138,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":796,"NA":798},{"trials":785,"activeCount":102},[],{"trials":787,"activeCount":102},[],{"trials":789,"activeCount":102},[],{"trials":791,"activeCount":138,"soonestReadout":653},[792],{"nctId":749,"briefTitle":750,"status":126,"phases":793,"primaryCompletion":653,"completion":653,"start":752,"enrollment":753,"conditions":794,"interventions":795},[92],[755],[738,757,758,759],{"trials":797,"activeCount":102},[],{"trials":799,"activeCount":102},[],{"intervention":759,"totalTrials":138,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":814,"NA":816},{"trials":803,"activeCount":102},[],{"trials":805,"activeCount":102},[],{"trials":807,"activeCount":102},[],{"trials":809,"activeCount":138,"soonestReadout":653},[810],{"nctId":749,"briefTitle":750,"status":126,"phases":811,"primaryCompletion":653,"completion":653,"start":752,"enrollment":753,"conditions":812,"interventions":813},[92],[755],[738,757,758,759],{"trials":815,"activeCount":102},[],{"trials":817,"activeCount":102},[],{"intervention":819,"totalTrials":138,"cells":820},"Canagliflozin 300Mg Tab",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":822,"activeCount":102},[],{"trials":824,"activeCount":102},[],{"trials":826,"activeCount":138,"soonestReadout":831},[827],{"nctId":828,"briefTitle":829,"status":126,"phases":830,"primaryCompletion":831,"completion":832,"start":338,"enrollment":833,"conditions":834,"interventions":836},"NCT06182839","Canagliflozin in Advanced Renal Disease With MRI Endpoints",[91],"2028-03-30","2029-03-30",92,[835],"ESRD, CKD Stage 4, CKD Stage 5",[819],{"trials":838,"activeCount":102},[],{"trials":840,"activeCount":102},[],{"trials":842,"activeCount":102},[],{"intervention":87,"totalTrials":138,"cells":844},{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":846,"activeCount":102},[],{"trials":848,"activeCount":102},[],{"trials":850,"activeCount":138,"soonestReadout":86},[851],{"nctId":84,"briefTitle":85,"status":126,"phases":852,"primaryCompletion":86,"completion":129,"start":853,"enrollment":854,"conditions":855,"interventions":857},[91],"2019-09-03",77,[856],"Prostate Cancer",[87],{"trials":859,"activeCount":102},[],{"trials":861,"activeCount":102},[],{"trials":863,"activeCount":102},[],{"intervention":865,"totalTrials":138,"cells":866},"Inactivated influenza vaccine (IIV) at baseline",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":868,"activeCount":102},[],{"trials":870,"activeCount":102},[],{"trials":872,"activeCount":138,"soonestReadout":877},[873],{"nctId":874,"briefTitle":875,"status":126,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":889},"NCT06599658","COVID-19 Booster and IIV Schedule in Immunocompromised Hosts",[91],"2027-03-31","2024-11-20",660,[881,882,883,884,885,886,887,888],"COVID 19","Influenza","Rheumatoid Arthritis (RA)","Systemic Lupus Erthematosus","Inflammatory Bowel Disease","Solid Organ Transplant Recipients","Immunocompromised Host","People Living With HIV",[865,890,891,892],"COVID-19 Vaccines at a 3-month interval","Inactivated influenza vaccine at Month 1","COVID-19 Vaccines at a 6-month interval",{"trials":894,"activeCount":102},[],{"trials":896,"activeCount":102},[],{"trials":898,"activeCount":102},[],{"intervention":890,"totalTrials":138,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":902,"activeCount":102},[],{"trials":904,"activeCount":102},[],{"trials":906,"activeCount":138,"soonestReadout":877},[907],{"nctId":874,"briefTitle":875,"status":126,"phases":908,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":909,"interventions":910},[91],[881,882,883,884,885,886,887,888],[865,890,891,892],{"trials":912,"activeCount":102},[],{"trials":914,"activeCount":102},[],{"trials":916,"activeCount":102},[],{"intervention":891,"totalTrials":138,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":920,"activeCount":102},[],{"trials":922,"activeCount":102},[],{"trials":924,"activeCount":138,"soonestReadout":877},[925],{"nctId":874,"briefTitle":875,"status":126,"phases":926,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":927,"interventions":928},[91],[881,882,883,884,885,886,887,888],[865,890,891,892],{"trials":930,"activeCount":102},[],{"trials":932,"activeCount":102},[],{"trials":934,"activeCount":102},[],{"intervention":892,"totalTrials":138,"cells":936},{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":947,"PHASE4":949,"NA":951},{"trials":938,"activeCount":102},[],{"trials":940,"activeCount":102},[],{"trials":942,"activeCount":138,"soonestReadout":877},[943],{"nctId":874,"briefTitle":875,"status":126,"phases":944,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":945,"interventions":946},[91],[881,882,883,884,885,886,887,888],[865,890,891,892],{"trials":948,"activeCount":102},[],{"trials":950,"activeCount":102},[],{"trials":952,"activeCount":102},[],{"intervention":954,"totalTrials":138,"cells":955},"Canagliflozin 300 MG",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":957,"activeCount":102},[],{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":138,"soonestReadout":966},[962],{"nctId":963,"briefTitle":964,"status":126,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":972},"NCT06913647","Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis",[91],"2028-02-28","2028-12-31","2026-02-01",30,[230,971],"CKD (Chronic Kidney Disease) Stage 5D",[954],{"trials":974,"activeCount":102},[],{"trials":976,"activeCount":102},[],{"trials":978,"activeCount":102},[],{"intervention":72,"totalTrials":138,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":982,"activeCount":102},[],{"trials":984,"activeCount":102},[],{"trials":986,"activeCount":138,"soonestReadout":71},[987],{"nctId":69,"briefTitle":70,"status":126,"phases":988,"primaryCompletion":71,"completion":71,"start":989,"enrollment":990,"conditions":991,"interventions":996},[91],"2025-12-28",69,[992,993,994,995],"Analgesia","Pain, Acute","Upper Extremity Surgery","Nerve Block",[72,997,998],"dexmedetomidine (perineural) 1 mcg\u002Fkg","dexmedetomidine (perineural) 1.33 mcg\u002Fkg",{"trials":1000,"activeCount":102},[],{"trials":1002,"activeCount":102},[],{"trials":1004,"activeCount":102},[],{"intervention":997,"totalTrials":138,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":1008,"activeCount":102},[],{"trials":1010,"activeCount":102},[],{"trials":1012,"activeCount":138,"soonestReadout":71},[1013],{"nctId":69,"briefTitle":70,"status":126,"phases":1014,"primaryCompletion":71,"completion":71,"start":989,"enrollment":990,"conditions":1015,"interventions":1016},[91],[992,993,994,995],[72,997,998],{"trials":1018,"activeCount":102},[],{"trials":1020,"activeCount":102},[],{"trials":1022,"activeCount":102},[],{"intervention":998,"totalTrials":138,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1026,"activeCount":102},[],{"trials":1028,"activeCount":102},[],{"trials":1030,"activeCount":138,"soonestReadout":71},[1031],{"nctId":69,"briefTitle":70,"status":126,"phases":1032,"primaryCompletion":71,"completion":71,"start":989,"enrollment":990,"conditions":1033,"interventions":1034},[91],[992,993,994,995],[72,997,998],{"trials":1036,"activeCount":102},[],{"trials":1038,"activeCount":102},[],{"trials":1040,"activeCount":102},[],{"intervention":42,"totalTrials":1042,"cells":1043},3,{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1059,"PHASE3":1068,"PHASE4":1070,"NA":1072},{"trials":1045,"activeCount":102},[],{"trials":1047,"activeCount":102},[1048],{"nctId":1049,"briefTitle":1050,"status":464,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT02659306","Metformin Immunotherapy in HIV Infection",[90],"2018-08-14","2020-02","2016-09",22,[1057],"HIV Infection",[42],{"trials":1060,"activeCount":138,"soonestReadout":41},[1061],{"nctId":39,"briefTitle":40,"status":225,"phases":1062,"primaryCompletion":41,"completion":1063,"start":1064,"enrollment":12,"conditions":1065,"interventions":1067},[91],"2027-02-28","2015-03",[1066],"Glioblastoma Multiforme",[42],{"trials":1069,"activeCount":102},[],{"trials":1071,"activeCount":102},[],{"trials":1073,"activeCount":102},[1074],{"nctId":1075,"briefTitle":1076,"status":1077,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":34,"conditions":1081,"interventions":1085},"NCT02393573","Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism","TERMINATED",[94],"2018-03","2015-11",[1082,1083,1084],"Pre-Diabetes","Major Lung or Abdominal Surgery","Insulin Resistance",[42],{"intervention":82,"totalTrials":138,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1089,"activeCount":102},[],{"trials":1091,"activeCount":138,"soonestReadout":81},[1092],{"nctId":79,"briefTitle":80,"status":157,"phases":1093,"primaryCompletion":81,"completion":81,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1100},[90],"2026-04-01",60,[1097,1098,1099],"Tuberculosis Infection","Healthy Volunteer","Breastfeeding",[82,1101,1102,1103,1104,1105],"High dose rifampicin","Standard dose isoniazid","Standard dose levofloxacin","Standard dose rifapentine","Standard dose bedaquiline",{"trials":1107,"activeCount":102},[],{"trials":1109,"activeCount":102},[],{"trials":1111,"activeCount":102},[],{"trials":1113,"activeCount":102},[],{"intervention":1101,"totalTrials":138,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1117,"activeCount":102},[],{"trials":1119,"activeCount":138,"soonestReadout":81},[1120],{"nctId":79,"briefTitle":80,"status":157,"phases":1121,"primaryCompletion":81,"completion":81,"start":1094,"enrollment":1095,"conditions":1122,"interventions":1123},[90],[1097,1098,1099],[82,1101,1102,1103,1104,1105],{"trials":1125,"activeCount":102},[],{"trials":1127,"activeCount":102},[],{"trials":1129,"activeCount":102},[],{"trials":1131,"activeCount":102},[],{"intervention":1102,"totalTrials":138,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1142,"PHASE3":1144,"PHASE4":1146,"NA":1148},{"trials":1135,"activeCount":102},[],{"trials":1137,"activeCount":138,"soonestReadout":81},[1138],{"nctId":79,"briefTitle":80,"status":157,"phases":1139,"primaryCompletion":81,"completion":81,"start":1094,"enrollment":1095,"conditions":1140,"interventions":1141},[90],[1097,1098,1099],[82,1101,1102,1103,1104,1105],{"trials":1143,"activeCount":102},[],{"trials":1145,"activeCount":102},[],{"trials":1147,"activeCount":102},[],{"trials":1149,"activeCount":102},[],{"intervention":1103,"totalTrials":138,"cells":1151},{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1153,"activeCount":102},[],{"trials":1155,"activeCount":138,"soonestReadout":81},[1156],{"nctId":79,"briefTitle":80,"status":157,"phases":1157,"primaryCompletion":81,"completion":81,"start":1094,"enrollment":1095,"conditions":1158,"interventions":1159},[90],[1097,1098,1099],[82,1101,1102,1103,1104,1105],{"trials":1161,"activeCount":102},[],{"trials":1163,"activeCount":102},[],{"trials":1165,"activeCount":102},[],{"trials":1167,"activeCount":102},[],{"intervention":1104,"totalTrials":138,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1171,"activeCount":102},[],{"trials":1173,"activeCount":138,"soonestReadout":81},[1174],{"nctId":79,"briefTitle":80,"status":157,"phases":1175,"primaryCompletion":81,"completion":81,"start":1094,"enrollment":1095,"conditions":1176,"interventions":1177},[90],[1097,1098,1099],[82,1101,1102,1103,1104,1105],{"trials":1179,"activeCount":102},[],{"trials":1181,"activeCount":102},[],{"trials":1183,"activeCount":102},[],{"trials":1185,"activeCount":102},[],{"intervention":1105,"totalTrials":138,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1196,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1189,"activeCount":102},[],{"trials":1191,"activeCount":138,"soonestReadout":81},[1192],{"nctId":79,"briefTitle":80,"status":157,"phases":1193,"primaryCompletion":81,"completion":81,"start":1094,"enrollment":1095,"conditions":1194,"interventions":1195},[90],[1097,1098,1099],[82,1101,1102,1103,1104,1105],{"trials":1197,"activeCount":102},[],{"trials":1199,"activeCount":102},[],{"trials":1201,"activeCount":102},[],{"trials":1203,"activeCount":102},[],{"intervention":1205,"totalTrials":138,"cells":1206},"SGLT-2 inhibitor",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1222,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1208,"activeCount":102},[],{"trials":1210,"activeCount":138,"soonestReadout":1215},[1211],{"nctId":1212,"briefTitle":1213,"status":126,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1221},"NCT06753994","Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors",[90],"2027-01-01","2024-12-05",24,[1219,1220,684],"Diabetes","Type1diabetes",[1205],{"trials":1223,"activeCount":102},[],{"trials":1225,"activeCount":102},[],{"trials":1227,"activeCount":102},[],{"trials":1229,"activeCount":102},[],{"intervention":47,"totalTrials":138,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1233,"activeCount":102},[],{"trials":1235,"activeCount":138,"soonestReadout":46},[1236],{"nctId":44,"briefTitle":45,"status":225,"phases":1237,"primaryCompletion":46,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1243},[90],"2024-12","2019-09-19",20,[1242],"Birth Asphyxia",[47],{"trials":1245,"activeCount":102},[],{"trials":1247,"activeCount":102},[],{"trials":1249,"activeCount":102},[],{"trials":1251,"activeCount":102},[],{"intervention":1253,"totalTrials":98,"cells":1254},"Fosigotifator",{"EARLY_PHASE1":1255,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1256,"activeCount":138,"soonestReadout":1261},[1257],{"nctId":1258,"briefTitle":1259,"status":225,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":138,"conditions":1264,"interventions":1267},"NCT07272525","Research Study for Single-Patient Treatment of Cree Leukoencephalopathy\u002FVanishing White Matter Disease",[89],"2027-11-30","2027-12-31","2024-11-14",[1265,1266],"Cree Leukoencephalopathy","Vanishing White Matter",[1253],{"trials":1269,"activeCount":102},[],{"trials":1271,"activeCount":102},[],{"trials":1273,"activeCount":102},[],{"trials":1275,"activeCount":102},[],{"trials":1277,"activeCount":138,"soonestReadout":1282},[1278],{"nctId":1279,"briefTitle":1280,"status":225,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":138,"conditions":1284,"interventions":1285},"NCT07300397","Single Patient Investigational Treatment for Cree Leukoencephalopathy",[94],"2029-01-03","2025-12-03",[1265],[1253],{"intervention":77,"totalTrials":138,"cells":1287},{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1289,"activeCount":102},[],{"trials":1291,"activeCount":102},[],{"trials":1293,"activeCount":102},[],{"trials":1295,"activeCount":102},[],{"trials":1297,"activeCount":102},[],{"trials":1299,"activeCount":138,"soonestReadout":76},[1300],{"nctId":74,"briefTitle":75,"status":126,"phases":1301,"primaryCompletion":76,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1309},[94],"2026-12","2023-11-08",70,[1306,1307,1308],"Liver Dysfunction","Liver Metastasis Colon Cancer","Liver Regeneration",[77],{"intervention":57,"totalTrials":138,"cells":1311},{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1320,"NA":1322},{"trials":1313,"activeCount":102},[],{"trials":1315,"activeCount":102},[],{"trials":1317,"activeCount":102},[],{"trials":1319,"activeCount":102},[],{"trials":1321,"activeCount":102},[],{"trials":1323,"activeCount":138,"soonestReadout":56},[1324],{"nctId":54,"briefTitle":55,"status":126,"phases":1325,"primaryCompletion":56,"completion":56,"start":1326,"enrollment":437,"conditions":1327,"interventions":1330},[94],"2025-09-01",[1328,1329],"Digestive Health","Gastrointestinal Health",[57],{"intervention":1332,"totalTrials":98,"cells":1333},"Saline",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1365},{"trials":1335,"activeCount":102},[],{"trials":1337,"activeCount":102},[],{"trials":1339,"activeCount":102},[],{"trials":1341,"activeCount":102},[],{"trials":1343,"activeCount":102},[1344,1355],{"nctId":1345,"briefTitle":1346,"status":464,"phases":1347,"primaryCompletion":1064,"completion":1080,"start":1348,"enrollment":1349,"conditions":1350,"interventions":1353},"NCT02618772","Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department",[93],"2010-01",79,[1351,1352],"Anxiety","Lacerations",[1354,1332],"Midazolam",{"nctId":1356,"briefTitle":1357,"status":112,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1240,"conditions":1361,"interventions":1363},"NCT01328132","Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant",[93],"2011-10","2011-03",[1362],"Other Complications of Liver Transplant",[1332,1364],"25% albumin",{"trials":1366,"activeCount":102},[],{"intervention":456,"totalTrials":98,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1379,"PHASE4":1381,"NA":1394},{"trials":1370,"activeCount":102},[],{"trials":1372,"activeCount":102},[],{"trials":1374,"activeCount":102},[1375],{"nctId":446,"briefTitle":447,"status":112,"phases":1376,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":1377,"interventions":1378},[90,91],[454],[456,436],{"trials":1380,"activeCount":102},[],{"trials":1382,"activeCount":102},[1383],{"nctId":1384,"briefTitle":1385,"status":112,"phases":1386,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":358,"conditions":1390,"interventions":1393},"NCT05755334","Ropivacaine Pharmacokinetics After Erector Spinae Block",[93],"2024-03-01","2024-11-01","2023-06-01",[1391,1392],"Pain","Spinal Fusion",[456],{"trials":1395,"activeCount":102},[],{"intervention":1397,"totalTrials":138,"cells":1398},"PEG\u002Felectrolytes 2L\u002F2L split dose",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1420},{"trials":1400,"activeCount":102},[],{"trials":1402,"activeCount":102},[],{"trials":1404,"activeCount":102},[],{"trials":1406,"activeCount":102},[],{"trials":1408,"activeCount":102},[1409],{"nctId":1410,"briefTitle":1411,"status":1077,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1418},"NCT02119000","Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy",[93],"2020-01","2015-08",82,[1417],"Hospitalized Patients",[1397,1419],"Bisacodyl 15 mg and PEG\u002Felectrolytes 1L\u002F1L split dose",{"trials":1421,"activeCount":102},[],{"intervention":1419,"totalTrials":138,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1438},{"trials":1425,"activeCount":102},[],{"trials":1427,"activeCount":102},[],{"trials":1429,"activeCount":102},[],{"trials":1431,"activeCount":102},[],{"trials":1433,"activeCount":102},[1434],{"nctId":1410,"briefTitle":1411,"status":1077,"phases":1435,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1436,"interventions":1437},[93],[1417],[1397,1419],{"trials":1439,"activeCount":102},[],{"intervention":1354,"totalTrials":138,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1450,"NA":1456},{"trials":1443,"activeCount":102},[],{"trials":1445,"activeCount":102},[],{"trials":1447,"activeCount":102},[],{"trials":1449,"activeCount":102},[],{"trials":1451,"activeCount":102},[1452],{"nctId":1345,"briefTitle":1346,"status":464,"phases":1453,"primaryCompletion":1064,"completion":1080,"start":1348,"enrollment":1349,"conditions":1454,"interventions":1455},[93],[1351,1352],[1354,1332],{"trials":1457,"activeCount":102},[],{"intervention":1459,"totalTrials":138,"cells":1460},"Switch to Triumeq",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1480},{"trials":1462,"activeCount":102},[],{"trials":1464,"activeCount":102},[],{"trials":1466,"activeCount":102},[],{"trials":1468,"activeCount":102},[],{"trials":1470,"activeCount":102},[1471],{"nctId":1472,"briefTitle":1473,"status":464,"phases":1474,"primaryCompletion":1475,"completion":1476,"start":1080,"enrollment":1477,"conditions":1478,"interventions":1479},"NCT02354053","Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations",[93],"2018-07-03","2019-07-02",27,[28],[1459],{"trials":1481,"activeCount":102},[],{"intervention":1483,"totalTrials":138,"cells":1484},"HPV vaccine, Gardasil 9",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1493,"NA":1506},{"trials":1486,"activeCount":102},[],{"trials":1488,"activeCount":102},[],{"trials":1490,"activeCount":102},[],{"trials":1492,"activeCount":102},[],{"trials":1494,"activeCount":102},[1495],{"nctId":1496,"briefTitle":1497,"status":464,"phases":1498,"primaryCompletion":1499,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1504},"NCT01824537","Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study",[93],"2022-11-18","2014-01",372,[1503],"Human Papillomavirus Infection",[1483,1505],"Hepatitis A vaccine",{"trials":1507,"activeCount":102},[],{"intervention":1505,"totalTrials":138,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1518,"NA":1524},{"trials":1511,"activeCount":102},[],{"trials":1513,"activeCount":102},[],{"trials":1515,"activeCount":102},[],{"trials":1517,"activeCount":102},[],{"trials":1519,"activeCount":102},[1520],{"nctId":1496,"briefTitle":1497,"status":464,"phases":1521,"primaryCompletion":1499,"completion":1499,"start":1500,"enrollment":1501,"conditions":1522,"interventions":1523},[93],[1503],[1483,1505],{"trials":1525,"activeCount":102},[],{"intervention":1527,"totalTrials":138,"cells":1528},"Methylphenidate or amphetamine product",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1550},{"trials":1530,"activeCount":102},[],{"trials":1532,"activeCount":102},[],{"trials":1534,"activeCount":102},[],{"trials":1536,"activeCount":102},[],{"trials":1538,"activeCount":102},[1539],{"nctId":1540,"briefTitle":1541,"status":112,"phases":1542,"primaryCompletion":1543,"completion":1544,"start":1545,"enrollment":1546,"conditions":1547,"interventions":1549},"NCT02566824","Cognitive Behavioral Therapy for Adolescents With Attention-Deficit \u002F Hyperactivity Disorder",[93],"2020-08","2020-10","2010-10",216,[1548],"Attention Deficit Hyperactivity Disorder",[1527],{"trials":1551,"activeCount":102},[],{"intervention":1553,"totalTrials":138,"cells":1554},"Bupropion",{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1561,"PHASE4":1563,"NA":1575},{"trials":1556,"activeCount":102},[],{"trials":1558,"activeCount":102},[],{"trials":1560,"activeCount":102},[],{"trials":1562,"activeCount":102},[],{"trials":1564,"activeCount":102},[1565],{"nctId":1566,"briefTitle":1567,"status":112,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1574},"NCT01583023","Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression",[93],"2015-04","2014-04",45,[1573],"Bipolar Disorder",[1553],{"trials":1576,"activeCount":102},[],{"intervention":1578,"totalTrials":138,"cells":1579},"Empagliflozin 25 MG",{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1586,"PHASE4":1588,"NA":1602},{"trials":1581,"activeCount":102},[],{"trials":1583,"activeCount":102},[],{"trials":1585,"activeCount":102},[],{"trials":1587,"activeCount":102},[],{"trials":1589,"activeCount":102},[1590],{"nctId":1591,"briefTitle":1592,"status":464,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1601},"NCT05305495","Empagliflozin in Acute Heart Failure",[93],"2026-02-15","2026-03-10","2022-12-22",25,[1599,1600],"Acute Heart Failure","Chronic Kidney Diseases",[1578],{"trials":1603,"activeCount":102},[],{"intervention":1605,"totalTrials":138,"cells":1606},"Daptomycin",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1615,"NA":1629},{"trials":1608,"activeCount":102},[],{"trials":1610,"activeCount":102},[],{"trials":1612,"activeCount":102},[],{"trials":1614,"activeCount":102},[],{"trials":1616,"activeCount":102},[1617],{"nctId":1618,"briefTitle":1619,"status":464,"phases":1620,"primaryCompletion":1621,"completion":1622,"start":1623,"enrollment":1624,"conditions":1625,"interventions":1628},"NCT02972983","Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia",[93],"2019-07","2019-09","2016-12-01",102,[1626,1627],"Methicillin Susceptible Staphylococcus Aureus Septicemia","Bacteremia",[1605],{"trials":1630,"activeCount":102},[],{"intervention":1632,"totalTrials":138,"cells":1633},"Ticagrelor 90mg",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1642,"NA":1657},{"trials":1635,"activeCount":102},[],{"trials":1637,"activeCount":102},[],{"trials":1639,"activeCount":102},[],{"trials":1641,"activeCount":102},[],{"trials":1643,"activeCount":102},[1644],{"nctId":1645,"briefTitle":1646,"status":464,"phases":1647,"primaryCompletion":1648,"completion":1649,"start":1650,"enrollment":1651,"conditions":1652,"interventions":1654},"NCT04057300","Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes",[93],"2022-04-01","2023-04-01","2018-10-01",1038,[1653],"Acute Coronary Syndrome",[1632,1655,1656],"Clopidogrel 75mg","acetylsalicylic acid (ASA) 81mg",{"trials":1658,"activeCount":102},[],{"intervention":1655,"totalTrials":138,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1667,"PHASE4":1669,"NA":1675},{"trials":1662,"activeCount":102},[],{"trials":1664,"activeCount":102},[],{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":102},[],{"trials":1670,"activeCount":102},[1671],{"nctId":1645,"briefTitle":1646,"status":464,"phases":1672,"primaryCompletion":1648,"completion":1649,"start":1650,"enrollment":1651,"conditions":1673,"interventions":1674},[93],[1653],[1632,1655,1656],{"trials":1676,"activeCount":102},[],{"intervention":1656,"totalTrials":138,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1685,"PHASE4":1687,"NA":1693},{"trials":1680,"activeCount":102},[],{"trials":1682,"activeCount":102},[],{"trials":1684,"activeCount":102},[],{"trials":1686,"activeCount":102},[],{"trials":1688,"activeCount":102},[1689],{"nctId":1645,"briefTitle":1646,"status":464,"phases":1690,"primaryCompletion":1648,"completion":1649,"start":1650,"enrollment":1651,"conditions":1691,"interventions":1692},[93],[1653],[1632,1655,1656],{"trials":1694,"activeCount":102},[],{"intervention":1696,"totalTrials":138,"cells":1697},"Integrase Inhibitor",{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1706,"NA":1717},{"trials":1699,"activeCount":102},[],{"trials":1701,"activeCount":102},[],{"trials":1703,"activeCount":102},[],{"trials":1705,"activeCount":102},[],{"trials":1707,"activeCount":102},[1708],{"nctId":1709,"briefTitle":1710,"status":464,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1716},"NCT02691065","Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection",[93],"2021-03-31","2017-01-20",6,[36],[1696],{"trials":1718,"activeCount":102},[],{"intervention":1720,"totalTrials":138,"cells":1721},"inhaled fluticasone 750 mcg\u002Fday twice daily until 2 days without symptoms",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1728,"PHASE4":1730,"NA":1742},{"trials":1723,"activeCount":102},[],{"trials":1725,"activeCount":102},[],{"trials":1727,"activeCount":102},[],{"trials":1729,"activeCount":102},[],{"trials":1731,"activeCount":102},[1732],{"nctId":1733,"briefTitle":1734,"status":464,"phases":1735,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1741},"NCT00238927","Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma",[93],"2005-09","1999-11",150,[1740],"Asthma",[1720],{"trials":1743,"activeCount":102},[],{"intervention":1745,"totalTrials":138,"cells":1746},"Albendazole",{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1751,"PHASE3":1753,"PHASE4":1755,"NA":1768},{"trials":1748,"activeCount":102},[],{"trials":1750,"activeCount":102},[],{"trials":1752,"activeCount":102},[],{"trials":1754,"activeCount":102},[],{"trials":1756,"activeCount":102},[1757],{"nctId":1758,"briefTitle":1759,"status":464,"phases":1760,"primaryCompletion":1761,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1767},"NCT01748929","Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth",[93],"2015-02-13","2016-09-16","2014-02-24",1010,[1766],"Intestinal Diseases, Parasitic",[1745],{"trials":1769,"activeCount":102},[],{"intervention":1771,"totalTrials":138,"cells":1772},"propofol",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1793},{"trials":1774,"activeCount":102},[],{"trials":1776,"activeCount":102},[],{"trials":1778,"activeCount":102},[],{"trials":1780,"activeCount":102},[],{"trials":1782,"activeCount":102},[1783],{"nctId":1784,"briefTitle":1785,"status":464,"phases":1786,"primaryCompletion":1787,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1792},"NCT01019746","Controlled Propofol Administration",[93],"2008-05","2007-08",40,[1791],"HYPNOSIS",[1771],{"trials":1794,"activeCount":102},[],{"intervention":1796,"totalTrials":138,"cells":1797},"Ranibizumab",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1819},{"trials":1799,"activeCount":102},[],{"trials":1801,"activeCount":102},[],{"trials":1803,"activeCount":102},[],{"trials":1805,"activeCount":102},[],{"trials":1807,"activeCount":102},[1808],{"nctId":1809,"briefTitle":1810,"status":112,"phases":1811,"primaryCompletion":1812,"completion":1812,"start":1813,"enrollment":1814,"conditions":1815,"interventions":1818},"NCT00813891","Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration",[93],"2009-12","2009-01",180,[1816,1817],"Macular Degeneration","Visual Acuity",[1796,1796,1796],{"trials":1820,"activeCount":102},[],{"intervention":1364,"totalTrials":138,"cells":1822},{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1837},{"trials":1824,"activeCount":102},[],{"trials":1826,"activeCount":102},[],{"trials":1828,"activeCount":102},[],{"trials":1830,"activeCount":102},[],{"trials":1832,"activeCount":102},[1833],{"nctId":1356,"briefTitle":1357,"status":112,"phases":1834,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":1240,"conditions":1835,"interventions":1836},[93],[1362],[1332,1364],{"trials":1838,"activeCount":102},[],{"intervention":1840,"totalTrials":138,"cells":1841},"Mebendazole",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1862},{"trials":1843,"activeCount":102},[],{"trials":1845,"activeCount":102},[],{"trials":1847,"activeCount":102},[],{"trials":1849,"activeCount":102},[],{"trials":1851,"activeCount":102},[1852],{"nctId":1853,"briefTitle":1854,"status":464,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1861},"NCT01314937","The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas",[93],"2013-07","2011-09",1760,[1860,1766],"Malnutrition",[1840],{"trials":1863,"activeCount":102},[],{"intervention":1865,"totalTrials":138,"cells":1866},"Ritalin",{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1885},{"trials":1868,"activeCount":102},[],{"trials":1870,"activeCount":102},[],{"trials":1872,"activeCount":102},[],{"trials":1874,"activeCount":102},[],{"trials":1876,"activeCount":102},[1877],{"nctId":1878,"briefTitle":1879,"status":464,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1737,"enrollment":1882,"conditions":1883,"interventions":1884},"NCT00483106","Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)",[93],"2020-03-31",885,[1548],[1865],{"trials":1886,"activeCount":102},[],{"intervention":1888,"totalTrials":138,"cells":1889},"Double dose of Salmeterol + Fluticasone Propionate",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1896,"PHASE4":1898,"NA":1911},{"trials":1891,"activeCount":102},[],{"trials":1893,"activeCount":102},[],{"trials":1895,"activeCount":102},[],{"trials":1897,"activeCount":102},[],{"trials":1899,"activeCount":102},[1900],{"nctId":1901,"briefTitle":1902,"status":464,"phases":1903,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":1907,"interventions":1909},"NCT02136875","Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation",[93],"2010-08","2008-07",37,[1908,31],"COPD",[1888,1910],"Self-administered prescription",{"trials":1912,"activeCount":102},[],{"intervention":1910,"totalTrials":138,"cells":1914},{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1921,"PHASE4":1923,"NA":1929},{"trials":1916,"activeCount":102},[],{"trials":1918,"activeCount":102},[],{"trials":1920,"activeCount":102},[],{"trials":1922,"activeCount":102},[],{"trials":1924,"activeCount":102},[1925],{"nctId":1901,"briefTitle":1902,"status":464,"phases":1926,"primaryCompletion":1904,"completion":1904,"start":1905,"enrollment":1906,"conditions":1927,"interventions":1928},[93],[1908,31],[1888,1910],{"trials":1930,"activeCount":102},[],{"intervention":1932,"totalTrials":138,"cells":1933},"lansoprazole",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1956},{"trials":1935,"activeCount":102},[],{"trials":1937,"activeCount":102},[],{"trials":1939,"activeCount":102},[],{"trials":1941,"activeCount":102},[],{"trials":1943,"activeCount":102},[1944],{"nctId":1945,"briefTitle":1946,"status":112,"phases":1947,"primaryCompletion":451,"completion":1948,"start":1949,"enrollment":1950,"conditions":1951,"interventions":1955},"NCT02278081","The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale\u002FBlue Colored Turbinate",[93],"2017-01","2015-01",98,[1952,1953,1954],"Rhinitis","Nasal Obstruction","GERD",[1932],{"trials":1957,"activeCount":102},[],{"intervention":1959,"totalTrials":138,"cells":1960},"Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1967,"PHASE4":1969,"NA":1984},{"trials":1962,"activeCount":102},[],{"trials":1964,"activeCount":102},[],{"trials":1966,"activeCount":102},[],{"trials":1968,"activeCount":102},[],{"trials":1970,"activeCount":102},[1971],{"nctId":1972,"briefTitle":1973,"status":112,"phases":1974,"primaryCompletion":1975,"completion":1976,"start":1977,"enrollment":1978,"conditions":1979,"interventions":1982},"NCT04769713","Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures",[93],"2023-06-30","2023-09-30","2021-11-23",80,[1980,1981],"Pain Control","Liver Cancer",[1959,1983],"Injection of normal saline in the hepatic hilum for the sham procedure",{"trials":1985,"activeCount":102},[],{"intervention":1983,"totalTrials":138,"cells":1987},{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":2002},{"trials":1989,"activeCount":102},[],{"trials":1991,"activeCount":102},[],{"trials":1993,"activeCount":102},[],{"trials":1995,"activeCount":102},[],{"trials":1997,"activeCount":102},[1998],{"nctId":1972,"briefTitle":1973,"status":112,"phases":1999,"primaryCompletion":1975,"completion":1976,"start":1977,"enrollment":1978,"conditions":2000,"interventions":2001},[93],[1980,1981],[1959,1983],{"trials":2003,"activeCount":102},[],{"intervention":2005,"totalTrials":138,"cells":2006},"Sinemet CR",{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2015,"NA":2027},{"trials":2008,"activeCount":102},[],{"trials":2010,"activeCount":102},[],{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":102},[2017],{"nctId":2018,"briefTitle":2019,"status":464,"phases":2020,"primaryCompletion":2021,"completion":2021,"start":2022,"enrollment":753,"conditions":2023,"interventions":2026},"NCT03111485","Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease",[93],"2022-10-28","2017-05-24",[2024,2025],"Parkinson's Disease","Obstructive Sleep Apnea",[2005],{"trials":2028,"activeCount":102},[],{"intervention":2030,"totalTrials":138,"cells":2031},"HD-TIV",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2038,"PHASE4":2040,"NA":2054},{"trials":2033,"activeCount":102},[],{"trials":2035,"activeCount":102},[],{"trials":2037,"activeCount":102},[],{"trials":2039,"activeCount":102},[],{"trials":2041,"activeCount":102},[2042],{"nctId":2043,"briefTitle":2044,"status":464,"phases":2045,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2052},"NCT02936180","Standard Versus High Dose Inactivated Influenza Vaccine in RA",[93],"2018-07","2018-12","2016-10",279,[2051],"Rheumatoid Arthritis",[2030,2053],"SD-QIV",{"trials":2055,"activeCount":102},[],{"intervention":2053,"totalTrials":138,"cells":2057},{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2062,"PHASE3":2064,"PHASE4":2066,"NA":2072},{"trials":2059,"activeCount":102},[],{"trials":2061,"activeCount":102},[],{"trials":2063,"activeCount":102},[],{"trials":2065,"activeCount":102},[],{"trials":2067,"activeCount":102},[2068],{"nctId":2043,"briefTitle":2044,"status":464,"phases":2069,"primaryCompletion":2046,"completion":2047,"start":2048,"enrollment":2049,"conditions":2070,"interventions":2071},[93],[2051],[2030,2053],{"trials":2073,"activeCount":102},[],{"intervention":2075,"totalTrials":138,"cells":2076},"Isentress.",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2085,"NA":2098},{"trials":2078,"activeCount":102},[],{"trials":2080,"activeCount":102},[],{"trials":2082,"activeCount":102},[],{"trials":2084,"activeCount":102},[],{"trials":2086,"activeCount":102},[2087],{"nctId":2088,"briefTitle":2089,"status":464,"phases":2090,"primaryCompletion":2091,"completion":2092,"start":1064,"enrollment":2093,"conditions":2094,"interventions":2097},"NCT02210715","Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients",[93],"2019-01-30","2023-01-30",31,[36,2095,2096],"Fatty Liver","Nonalcoholic Steatohepatitis",[2075],{"trials":2099,"activeCount":102},[],{"intervention":2101,"totalTrials":98,"cells":2102},"Isoniazid",{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2109,"PHASE4":2132,"NA":2134},{"trials":2104,"activeCount":102},[],{"trials":2106,"activeCount":102},[],{"trials":2108,"activeCount":102},[],{"trials":2110,"activeCount":102},[2111,2122],{"nctId":2112,"briefTitle":2113,"status":464,"phases":2114,"primaryCompletion":2115,"completion":2115,"start":2116,"enrollment":2117,"conditions":2118,"interventions":2120},"NCT00931736","Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness",[92],"2017-04","2009-08",6031,[2119],"Latent Tuberculosis Infection",[2101,2121],"Rifampin",{"nctId":2123,"briefTitle":2124,"status":464,"phases":2125,"primaryCompletion":2126,"completion":2127,"start":2128,"enrollment":2129,"conditions":2130,"interventions":2131},"NCT00170209","Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)",[92],"2014-11","2015-05","2011-08",844,[2119],[2101,2121],{"trials":2133,"activeCount":102},[],{"trials":2135,"activeCount":102},[],{"intervention":2121,"totalTrials":98,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2144,"PHASE4":2154,"NA":2156},{"trials":2139,"activeCount":102},[],{"trials":2141,"activeCount":102},[],{"trials":2143,"activeCount":102},[],{"trials":2145,"activeCount":102},[2146,2150],{"nctId":2112,"briefTitle":2113,"status":464,"phases":2147,"primaryCompletion":2115,"completion":2115,"start":2116,"enrollment":2117,"conditions":2148,"interventions":2149},[92],[2119],[2101,2121],{"nctId":2123,"briefTitle":2124,"status":464,"phases":2151,"primaryCompletion":2126,"completion":2127,"start":2128,"enrollment":2129,"conditions":2152,"interventions":2153},[92],[2119],[2101,2121],{"trials":2155,"activeCount":102},[],{"trials":2157,"activeCount":102},[],{"intervention":2159,"totalTrials":98,"cells":2160},"Sodium Bicarbonate",{"EARLY_PHASE1":2161,"PHASE1":2172,"PHASE2":2174,"PHASE3":2176,"PHASE4":2190,"NA":2192},{"trials":2162,"activeCount":102},[2163],{"nctId":2164,"briefTitle":2165,"status":464,"phases":2166,"primaryCompletion":2167,"completion":1054,"start":2127,"enrollment":1240,"conditions":2168,"interventions":2170},"NCT03057535","Impact of NaHCO3- on Exercise Hyperpnea",[89],"2016-04",[2169],"Pulmonary Ventilation",[2159,2171],"Sodium Chloride",{"trials":2173,"activeCount":102},[],{"trials":2175,"activeCount":102},[],{"trials":2177,"activeCount":102},[2178],{"nctId":2179,"briefTitle":2180,"status":112,"phases":2181,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":452,"conditions":2185,"interventions":2187},"NCT00522756","Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy",[92],"2012-12","2013-03","2006-05",[2186],"Kidney Failure, Acute",[2188,2189],"Sodium bicarbonate","Sodium chloride",{"trials":2191,"activeCount":102},[],{"trials":2193,"activeCount":102},[],{"intervention":2171,"totalTrials":98,"cells":2195},{"EARLY_PHASE1":2196,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2212,"NA":2214},{"trials":2197,"activeCount":102},[2198],{"nctId":2164,"briefTitle":2165,"status":464,"phases":2199,"primaryCompletion":2167,"completion":1054,"start":2127,"enrollment":1240,"conditions":2200,"interventions":2201},[89],[2169],[2159,2171],{"trials":2203,"activeCount":102},[],{"trials":2205,"activeCount":102},[],{"trials":2207,"activeCount":102},[2208],{"nctId":2179,"briefTitle":2180,"status":112,"phases":2209,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":452,"conditions":2210,"interventions":2211},[92],[2186],[2188,2189],{"trials":2213,"activeCount":102},[],{"trials":2215,"activeCount":102},[],{"intervention":2217,"totalTrials":138,"cells":2218},"Moderna COVID-19 vaccine",{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2223,"PHASE3":2225,"PHASE4":2240,"NA":2242},{"trials":2220,"activeCount":102},[],{"trials":2222,"activeCount":102},[],{"trials":2224,"activeCount":102},[],{"trials":2226,"activeCount":102},[2227],{"nctId":2228,"briefTitle":2229,"status":464,"phases":2230,"primaryCompletion":2231,"completion":2232,"start":2233,"enrollment":2234,"conditions":2235,"interventions":2239},"NCT04806113","COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases",[92],"2021-06-13","2022-06-15","2021-03-11",220,[2236,2237,2051,2238],"Covid19","Rheumatic Diseases","SLE",[2217],{"trials":2241,"activeCount":102},[],{"trials":2243,"activeCount":102},[],{"intervention":2245,"totalTrials":138,"cells":2246},"Various vaccines",{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2262,"NA":2264},{"trials":2248,"activeCount":102},[],{"trials":2250,"activeCount":102},[],{"trials":2252,"activeCount":102},[],{"trials":2254,"activeCount":102},[2255],{"nctId":2256,"briefTitle":2257,"status":2258,"phases":2259,"primaryCompletion":2128,"completion":2128,"start":1813,"enrollment":102,"conditions":2260,"interventions":2261},"NCT00785967","Immune Responses in Patients Treated With Raltegravir","WITHDRAWN",[92],[28],[2245],{"trials":2263,"activeCount":102},[],{"trials":2265,"activeCount":102},[],{"intervention":2267,"totalTrials":138,"cells":2268},"Alendronate",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2286,"NA":2288},{"trials":2270,"activeCount":102},[],{"trials":2272,"activeCount":102},[],{"trials":2274,"activeCount":102},[],{"trials":2276,"activeCount":102},[2277],{"nctId":2278,"briefTitle":2279,"status":112,"phases":2280,"completion":2281,"start":2282,"enrollment":26,"conditions":2283,"interventions":2285},"NCT00346190","The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.",[92],"2007-04","2003-01",[2284],"Osteoporosis",[2267],{"trials":2287,"activeCount":102},[],{"trials":2289,"activeCount":102},[],{"intervention":2291,"totalTrials":138,"cells":2292},"Intrathecal morphine",{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2311,"NA":2313},{"trials":2294,"activeCount":102},[],{"trials":2296,"activeCount":102},[],{"trials":2298,"activeCount":102},[],{"trials":2300,"activeCount":102},[2301],{"nctId":2302,"briefTitle":2303,"status":112,"phases":2304,"primaryCompletion":2305,"completion":2306,"start":1053,"enrollment":2307,"conditions":2308,"interventions":2310},"NCT04256642","Comparison of the Erector Spinae Plane Block Versus Intrathecal Morphine on Post-Cesarean Delivery Analgesia",[92],"2022-01","2023-01",160,[2309],"Cesarean Section Complications",[2291],{"trials":2312,"activeCount":102},[],{"trials":2314,"activeCount":102},[],{"intervention":2316,"totalTrials":138,"cells":2317},"Montelukast 10mg",{"EARLY_PHASE1":2318,"PHASE1":2320,"PHASE2":2322,"PHASE3":2324,"PHASE4":2336,"NA":2338},{"trials":2319,"activeCount":102},[],{"trials":2321,"activeCount":102},[],{"trials":2323,"activeCount":102},[],{"trials":2325,"activeCount":102},[2326],{"nctId":2327,"briefTitle":2328,"status":112,"phases":2329,"primaryCompletion":2306,"completion":2330,"start":2331,"enrollment":2332,"conditions":2333,"interventions":2335},"NCT04389411","The Covid-19 Outpatient Symptom Montelukast Oximetry Trial",[91,92],"2025-02","2022-11-01",250,[2334],"COVID-19",[2316],{"trials":2337,"activeCount":102},[],{"trials":2339,"activeCount":102},[],{"intervention":2341,"totalTrials":138,"cells":2342},"Fentanyl citrate solution sublingual",{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2349,"PHASE4":2361,"NA":2363},{"trials":2344,"activeCount":102},[],{"trials":2346,"activeCount":102},[],{"trials":2348,"activeCount":102},[],{"trials":2350,"activeCount":102},[2351],{"nctId":2352,"briefTitle":2353,"status":1077,"phases":2354,"primaryCompletion":2355,"completion":2356,"start":2357,"enrollment":1789,"conditions":2358,"interventions":2360},"NCT04004117","Effect of Sublingual Fentanyl on Breathlessness in COPD",[91,92],"2019-12-31","2026-02-04","2019-07-01",[2359],"Copd",[2341],{"trials":2362,"activeCount":102},[],{"trials":2364,"activeCount":102},[],{"intervention":2366,"totalTrials":138,"cells":2367},"oral methadone",{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2387,"NA":2389},{"trials":2369,"activeCount":102},[],{"trials":2371,"activeCount":102},[],{"trials":2373,"activeCount":102},[],{"trials":2375,"activeCount":102},[2376],{"nctId":2377,"briefTitle":2378,"status":112,"phases":2379,"primaryCompletion":2380,"completion":2047,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2385},"NCT02687347","Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain",[92],"2018-02","2016-02",204,[2384],"Pain, Intractable",[2366,2386],"oral morphine",{"trials":2388,"activeCount":102},[],{"trials":2390,"activeCount":102},[],{"intervention":2386,"totalTrials":138,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2397,"PHASE3":2399,"PHASE4":2405,"NA":2407},{"trials":2394,"activeCount":102},[],{"trials":2396,"activeCount":102},[],{"trials":2398,"activeCount":102},[],{"trials":2400,"activeCount":102},[2401],{"nctId":2377,"briefTitle":2378,"status":112,"phases":2402,"primaryCompletion":2380,"completion":2047,"start":2381,"enrollment":2382,"conditions":2403,"interventions":2404},[92],[2384],[2366,2386],{"trials":2406,"activeCount":102},[],{"trials":2408,"activeCount":102},[],{"intervention":2410,"totalTrials":138,"cells":2411},"Opioid analgesics",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2434,"NA":2436},{"trials":2413,"activeCount":102},[],{"trials":2415,"activeCount":102},[],{"trials":2417,"activeCount":102},[],{"trials":2419,"activeCount":102},[2420],{"nctId":2421,"briefTitle":2422,"status":464,"phases":2423,"primaryCompletion":2424,"completion":2425,"start":2426,"enrollment":2427,"conditions":2428,"interventions":2432},"NCT04254679","Pilot Trial: Postoperative Opioid-free Analgesia",[91,92],"2020-09-20","2020-12-03","2020-01-29",81,[2429,2430,2431],"Outpatient Surgery","Abdominal Surgery","Breast Surgery",[2410,2433],"Non-opioid analgesics",{"trials":2435,"activeCount":102},[],{"trials":2437,"activeCount":102},[],{"intervention":2433,"totalTrials":138,"cells":2439},{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2446,"PHASE4":2452,"NA":2454},{"trials":2441,"activeCount":102},[],{"trials":2443,"activeCount":102},[],{"trials":2445,"activeCount":102},[],{"trials":2447,"activeCount":102},[2448],{"nctId":2421,"briefTitle":2422,"status":464,"phases":2449,"primaryCompletion":2424,"completion":2425,"start":2426,"enrollment":2427,"conditions":2450,"interventions":2451},[91,92],[2429,2430,2431],[2410,2433],{"trials":2453,"activeCount":102},[],{"trials":2455,"activeCount":102},[],{"intervention":2457,"totalTrials":138,"cells":2458},"Ketotifen Fumarate",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2476,"NA":2478},{"trials":2460,"activeCount":102},[],{"trials":2462,"activeCount":102},[],{"trials":2464,"activeCount":102},[],{"trials":2466,"activeCount":102},[2467],{"nctId":2468,"briefTitle":2469,"status":464,"phases":2470,"primaryCompletion":1413,"completion":1413,"start":2471,"enrollment":2472,"conditions":2473,"interventions":2475},"NCT02984397","Chronic Widespread Pain and White Blood Cell Activation",[92],"2016-12",44,[2474],"Widespread Chronic Pain",[2457],{"trials":2477,"activeCount":102},[],{"trials":2479,"activeCount":102},[],{"intervention":2481,"totalTrials":138,"cells":2482},"zoledronic acid",{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2487,"PHASE3":2489,"PHASE4":2502,"NA":2504},{"trials":2484,"activeCount":102},[],{"trials":2486,"activeCount":102},[],{"trials":2488,"activeCount":102},[],{"trials":2490,"activeCount":102},[2491],{"nctId":2492,"briefTitle":2493,"status":464,"phases":2494,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":23,"conditions":2498,"interventions":2501},"NCT00798473","Zoledronate for Osteopenia in Pediatric Crohn's",[92],"2007-09","2008-11","2004-09",[2499,2500,2284],"Crohn's Disease","Osteopenia",[2481],{"trials":2503,"activeCount":102},[],{"trials":2505,"activeCount":102},[],{"intervention":2507,"totalTrials":138,"cells":2508},"Caffeine",{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2515,"PHASE4":2525,"NA":2527},{"trials":2510,"activeCount":102},[],{"trials":2512,"activeCount":102},[],{"trials":2514,"activeCount":102},[],{"trials":2516,"activeCount":102},[2517],{"nctId":2518,"briefTitle":2519,"status":464,"phases":2520,"primaryCompletion":2521,"completion":1623,"start":1570,"enrollment":2522,"conditions":2523,"interventions":2524},"NCT01738178","Caffeine as a Therapy for Parkinson's Disease",[92],"2016-05-01",119,[2024],[2507],{"trials":2526,"activeCount":102},[],{"trials":2528,"activeCount":102},[],{"intervention":2530,"totalTrials":138,"cells":2531},"Morphine",{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2536,"PHASE3":2538,"PHASE4":2548,"NA":2550},{"trials":2533,"activeCount":102},[],{"trials":2535,"activeCount":102},[],{"trials":2537,"activeCount":102},[],{"trials":2539,"activeCount":102},[2540],{"nctId":2541,"briefTitle":2542,"status":112,"phases":2543,"primaryCompletion":2544,"completion":2544,"start":2545,"enrollment":1240,"conditions":2546,"interventions":2547},"NCT01718496","Morphine, Dyspnea, Exercise and COPD",[92],"2016-08","2014-07",[31],[2530],{"trials":2549,"activeCount":102},[],{"trials":2551,"activeCount":102},[],{"intervention":2553,"totalTrials":138,"cells":2554},"Hydroxychloroquine",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2561,"PHASE4":2574,"NA":2576},{"trials":2556,"activeCount":102},[],{"trials":2558,"activeCount":102},[],{"trials":2560,"activeCount":102},[],{"trials":2562,"activeCount":102},[2563],{"nctId":2564,"briefTitle":2565,"status":1077,"phases":2566,"primaryCompletion":2567,"completion":2567,"start":2568,"enrollment":1304,"conditions":2569,"interventions":2573},"NCT04421664","Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)",[92],"2020-08-17","2020-03-25",[2570,2571,2572],"Corona Virus Infection","SARS-CoV Infection","Coronavirus",[2553],{"trials":2575,"activeCount":102},[],{"trials":2577,"activeCount":102},[],{"intervention":2579,"totalTrials":138,"cells":2580},"0.9% saline in 5% dextrose",{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2585,"PHASE3":2587,"PHASE4":2603,"NA":2605},{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":102},[],{"trials":2586,"activeCount":102},[],{"trials":2588,"activeCount":102},[2589],{"nctId":2590,"briefTitle":2591,"status":464,"phases":2592,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":2595,"conditions":2596,"interventions":2601},"NCT00457873","Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy",[92],"2008-04","2007-01",38,[2597,2598,2599,2600],"Gastroenteritis","Bronchiolitis","Sepsis","Urinary Tract Infection",[2579,2602],"0.45% saline in 5% dextrose",{"trials":2604,"activeCount":102},[],{"trials":2606,"activeCount":102},[],{"intervention":2602,"totalTrials":138,"cells":2608},{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2621,"NA":2623},{"trials":2610,"activeCount":102},[],{"trials":2612,"activeCount":102},[],{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":102},[2617],{"nctId":2590,"briefTitle":2591,"status":464,"phases":2618,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":2595,"conditions":2619,"interventions":2620},[92],[2597,2598,2599,2600],[2579,2602],{"trials":2622,"activeCount":102},[],{"trials":2624,"activeCount":102},[],{"intervention":2626,"totalTrials":138,"cells":2627},"mammalian Omega 3 Fatty acids",{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2646,"NA":2648},{"trials":2629,"activeCount":102},[],{"trials":2631,"activeCount":102},[],{"trials":2633,"activeCount":102},[],{"trials":2635,"activeCount":102},[2636],{"nctId":2637,"briefTitle":2638,"status":112,"phases":2639,"primaryCompletion":1569,"completion":2640,"start":1949,"enrollment":2641,"conditions":2642,"interventions":2645},"NCT02294149","Vit D3 and Omega 3 in Chemo Induced Neuropathy",[92],"2016-11",600,[2643,2644],"Cancer","Neuropathy",[2626],{"trials":2647,"activeCount":102},[],{"trials":2649,"activeCount":102},[],{"intervention":2651,"totalTrials":138,"cells":2652},"Aspirin",{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2657,"PHASE3":2659,"PHASE4":2673,"NA":2675},{"trials":2654,"activeCount":102},[],{"trials":2656,"activeCount":102},[],{"trials":2658,"activeCount":102},[],{"trials":2660,"activeCount":102},[2661],{"nctId":2662,"briefTitle":2663,"status":112,"phases":2664,"primaryCompletion":2665,"completion":2666,"start":2667,"enrollment":2668,"conditions":2669,"interventions":2672},"NCT03405974","Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip",[92],"2020-11-01","2021-11-01","2017-10-12",114,[2670,2671],"Osteonecrosis of Femoral Head","Osteonecrosis; Aseptic, Idiopathic",[2651],{"trials":2674,"activeCount":102},[],{"trials":2676,"activeCount":102},[],{"intervention":2678,"totalTrials":138,"cells":2679},"Rosuvastatin",{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2686,"PHASE4":2697,"NA":2699},{"trials":2681,"activeCount":102},[],{"trials":2683,"activeCount":102},[],{"trials":2685,"activeCount":102},[],{"trials":2687,"activeCount":102},[2688],{"nctId":2689,"briefTitle":2690,"status":464,"phases":2691,"primaryCompletion":2692,"completion":2692,"start":2693,"enrollment":480,"conditions":2694,"interventions":2696},"NCT01425398","A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery",[92],"2013-12","2011-11",[2695],"Valvular Cardiac Surgery",[2678],{"trials":2698,"activeCount":102},[],{"trials":2700,"activeCount":102},[],{"intervention":2702,"totalTrials":138,"cells":2703},"Dapsone 85 mg PO BID",{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2710,"PHASE4":2722,"NA":2724},{"trials":2705,"activeCount":102},[],{"trials":2707,"activeCount":102},[],{"trials":2709,"activeCount":102},[],{"trials":2711,"activeCount":102},[2712],{"nctId":2713,"briefTitle":2714,"status":112,"phases":2715,"primaryCompletion":2716,"completion":2717,"start":2718,"enrollment":2719,"conditions":2720,"interventions":2721},"NCT04935476","Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19",[92],"2022-03-31","2022-07-31","2021-11-22",3000,[2334],[2702],{"trials":2723,"activeCount":102},[],{"trials":2725,"activeCount":102},[],{"intervention":2727,"totalTrials":138,"cells":2728},"Normal Saline intranasal and placebo inhaler",{"EARLY_PHASE1":2729,"PHASE1":2731,"PHASE2":2733,"PHASE3":2735,"PHASE4":2749,"NA":2751},{"trials":2730,"activeCount":102},[],{"trials":2732,"activeCount":102},[],{"trials":2734,"activeCount":102},[],{"trials":2736,"activeCount":102},[2737],{"nctId":2738,"briefTitle":2739,"status":1077,"phases":2740,"primaryCompletion":2741,"completion":2742,"start":2743,"enrollment":2744,"conditions":2745,"interventions":2746},"NCT04435795","Inhaled Ciclesonide for Outpatients With COVID19",[91,92],"2021-06-08","2021-07-08","2020-09-15",215,[881],[2727,2747,2748],"Ciclesonide","Ciclesonide nasal",{"trials":2750,"activeCount":102},[],{"trials":2752,"activeCount":102},[],{"intervention":2747,"totalTrials":138,"cells":2754},{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2759,"PHASE3":2761,"PHASE4":2767,"NA":2769},{"trials":2756,"activeCount":102},[],{"trials":2758,"activeCount":102},[],{"trials":2760,"activeCount":102},[],{"trials":2762,"activeCount":102},[2763],{"nctId":2738,"briefTitle":2739,"status":1077,"phases":2764,"primaryCompletion":2741,"completion":2742,"start":2743,"enrollment":2744,"conditions":2765,"interventions":2766},[91,92],[881],[2727,2747,2748],{"trials":2768,"activeCount":102},[],{"trials":2770,"activeCount":102},[],{"intervention":2748,"totalTrials":138,"cells":2772},{"EARLY_PHASE1":2773,"PHASE1":2775,"PHASE2":2777,"PHASE3":2779,"PHASE4":2785,"NA":2787},{"trials":2774,"activeCount":102},[],{"trials":2776,"activeCount":102},[],{"trials":2778,"activeCount":102},[],{"trials":2780,"activeCount":102},[2781],{"nctId":2738,"briefTitle":2739,"status":1077,"phases":2782,"primaryCompletion":2741,"completion":2742,"start":2743,"enrollment":2744,"conditions":2783,"interventions":2784},[91,92],[881],[2727,2747,2748],{"trials":2786,"activeCount":102},[],{"trials":2788,"activeCount":102},[],{"intervention":2790,"totalTrials":138,"cells":2791},"basiliximab",{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2796,"PHASE3":2798,"PHASE4":2807,"NA":2809},{"trials":2793,"activeCount":102},[],{"trials":2795,"activeCount":102},[],{"trials":2797,"activeCount":102},[],{"trials":2799,"activeCount":102},[2800],{"nctId":2801,"briefTitle":2802,"status":112,"phases":2803,"completion":2593,"start":2281,"enrollment":12,"conditions":2804,"interventions":2806},"NCT00302497","EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function",[92],[2805],"Kidney Transplant",[2790],{"trials":2808,"activeCount":102},[],{"trials":2810,"activeCount":102},[],{"intervention":2812,"totalTrials":138,"cells":2813},"Aclidinium bromide\u002Fformoterol fumarate dihydrate",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2820,"PHASE4":2833,"NA":2835},{"trials":2815,"activeCount":102},[],{"trials":2817,"activeCount":102},[],{"trials":2819,"activeCount":102},[],{"trials":2821,"activeCount":102},[2822],{"nctId":2823,"briefTitle":2824,"status":464,"phases":2825,"primaryCompletion":2826,"completion":2827,"start":2828,"enrollment":2829,"conditions":2830,"interventions":2832},"NCT03104634","The Effects of Inhaled Aclidinium Bromide\u002FFormoterol Fumarate on Inspiratory Pleural Pressures in Smokers",[92],"2018-12-01","2019-02-01","2017-05-01",43,[2831],"Smoking",[2812],{"trials":2834,"activeCount":102},[],{"trials":2836,"activeCount":102},[],{"intervention":2838,"totalTrials":138,"cells":2839},"Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy",{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2844,"PHASE3":2846,"PHASE4":2858,"NA":2860},{"trials":2841,"activeCount":102},[],{"trials":2843,"activeCount":102},[],{"trials":2845,"activeCount":102},[],{"trials":2847,"activeCount":102},[2848],{"nctId":2849,"briefTitle":2850,"status":464,"phases":2851,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":2856,"interventions":2857},"NCT05205928","Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care",[91,92],"2024-04-15","2024-06-30","2022-10-02",28,[19,22],[2838],{"trials":2859,"activeCount":102},[],{"trials":2861,"activeCount":102},[],{"intervention":597,"totalTrials":138,"cells":2863},{"EARLY_PHASE1":2864,"PHASE1":2866,"PHASE2":2868,"PHASE3":2870,"PHASE4":2876,"NA":2878},{"trials":2865,"activeCount":102},[],{"trials":2867,"activeCount":102},[],{"trials":2869,"activeCount":102},[],{"trials":2871,"activeCount":102},[2872],{"nctId":587,"briefTitle":588,"status":464,"phases":2873,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":2874,"interventions":2875},[92],[595],[564,597],{"trials":2877,"activeCount":102},[],{"trials":2879,"activeCount":102},[],{"intervention":2881,"totalTrials":138,"cells":2882},"Lyumjev",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2901,"NA":2903},{"trials":2884,"activeCount":102},[],{"trials":2886,"activeCount":102},[],{"trials":2888,"activeCount":102},[],{"trials":2890,"activeCount":102},[2891],{"nctId":2892,"briefTitle":2893,"status":112,"phases":2894,"primaryCompletion":752,"completion":2895,"start":2896,"enrollment":969,"conditions":2897,"interventions":2899},"NCT06046417","A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes",[91,92],"2025-06","2023-11-30",[2898,22],"type1diabetes",[2900,2881],"Pramlintide",{"trials":2902,"activeCount":102},[],{"trials":2904,"activeCount":102},[],{"intervention":2906,"totalTrials":138,"cells":2907},"Myfortic",{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2914,"PHASE4":2924,"NA":2926},{"trials":2909,"activeCount":102},[],{"trials":2911,"activeCount":102},[],{"trials":2913,"activeCount":102},[],{"trials":2915,"activeCount":102},[2916],{"nctId":2917,"briefTitle":2918,"status":112,"phases":2919,"primaryCompletion":1812,"completion":1812,"start":2920,"enrollment":494,"conditions":2921,"interventions":2923},"NCT00468936","Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms",[92],"2007-05",[2922],"Heart Transplant Patients",[2906],{"trials":2925,"activeCount":102},[],{"trials":2927,"activeCount":102},[],{"intervention":2929,"totalTrials":138,"cells":2930},"Betaine",{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2935,"PHASE3":2937,"PHASE4":2948,"NA":2950},{"trials":2932,"activeCount":102},[],{"trials":2934,"activeCount":102},[],{"trials":2936,"activeCount":102},[],{"trials":2938,"activeCount":102},[2939],{"nctId":2940,"briefTitle":2941,"status":464,"phases":2942,"primaryCompletion":1949,"completion":2943,"start":2183,"enrollment":2944,"conditions":2945,"interventions":2947},"NCT01838941","Betaine and Peroxisome Biogenesis Disorders",[92],"2015-06",12,[2946],"Peroxisome Biogenesis Disorders",[2929],{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[],{"intervention":2953,"totalTrials":138,"cells":2954},"2 ml bupivacaine",{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2959,"PHASE3":2972,"PHASE4":2974,"NA":2976},{"trials":2956,"activeCount":102},[],{"trials":2958,"activeCount":102},[],{"trials":2960,"activeCount":102},[2961],{"nctId":2962,"briefTitle":2963,"status":464,"phases":2964,"primaryCompletion":2965,"completion":2966,"start":2967,"enrollment":12,"conditions":2968,"interventions":2970},"NCT01561274","ET 50 for Post Caesarean Section Spinal Hypotension",[91],"2014-03","2014-05","2012-03",[2969],"Hypotension",[2953,2971],"1.5 ml bupivicaine.",{"trials":2973,"activeCount":102},[],{"trials":2975,"activeCount":102},[],{"trials":2977,"activeCount":102},[],{"intervention":2971,"totalTrials":138,"cells":2979},{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2990,"PHASE4":2992,"NA":2994},{"trials":2981,"activeCount":102},[],{"trials":2983,"activeCount":102},[],{"trials":2985,"activeCount":102},[2986],{"nctId":2962,"briefTitle":2963,"status":464,"phases":2987,"primaryCompletion":2965,"completion":2966,"start":2967,"enrollment":12,"conditions":2988,"interventions":2989},[91],[2969],[2953,2971],{"trials":2991,"activeCount":102},[],{"trials":2993,"activeCount":102},[],{"trials":2995,"activeCount":102},[],{"intervention":2997,"totalTrials":138,"cells":2998},"TN-TC11M2 oral",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3014,"PHASE4":3016,"NA":3018},{"trials":3000,"activeCount":102},[],{"trials":3002,"activeCount":102},[],{"trials":3004,"activeCount":102},[3005],{"nctId":3006,"briefTitle":3007,"status":1077,"phases":3008,"primaryCompletion":3009,"completion":3009,"start":3010,"enrollment":26,"conditions":3011,"interventions":3012},"NCT03550352","Cannabinoids in PLWHIV on Effective ART",[91],"2022-05-31","2021-08-20",[28],[2997,3013],"TN-C200M2 oral",{"trials":3015,"activeCount":102},[],{"trials":3017,"activeCount":102},[],{"trials":3019,"activeCount":102},[],{"intervention":3013,"totalTrials":138,"cells":3021},{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3032,"PHASE4":3034,"NA":3036},{"trials":3023,"activeCount":102},[],{"trials":3025,"activeCount":102},[],{"trials":3027,"activeCount":102},[3028],{"nctId":3006,"briefTitle":3007,"status":1077,"phases":3029,"primaryCompletion":3009,"completion":3009,"start":3010,"enrollment":26,"conditions":3030,"interventions":3031},[91],[28],[2997,3013],{"trials":3033,"activeCount":102},[],{"trials":3035,"activeCount":102},[],{"trials":3037,"activeCount":102},[],{"intervention":3039,"totalTrials":138,"cells":3040},"FLOT",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3056,"PHASE4":3058,"NA":3060},{"trials":3042,"activeCount":102},[],{"trials":3044,"activeCount":102},[],{"trials":3046,"activeCount":102},[3047],{"nctId":3048,"briefTitle":3049,"status":464,"phases":3050,"primaryCompletion":2943,"completion":2943,"start":3051,"enrollment":26,"conditions":3052,"interventions":3055},"NCT01932580","Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma",[91],"2013-08",[3053,3054],"Gastric Adenocarcinoma","Esophageal Adenocarcinoma",[3039],{"trials":3057,"activeCount":102},[],{"trials":3059,"activeCount":102},[],{"trials":3061,"activeCount":102},[],{"intervention":3063,"totalTrials":138,"cells":3064},"N-acetylcysteine",{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3069,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3066,"activeCount":102},[],{"trials":3068,"activeCount":102},[],{"trials":3070,"activeCount":102},[3071],{"nctId":3072,"briefTitle":3073,"status":464,"phases":3074,"primaryCompletion":3075,"completion":3076,"start":3077,"enrollment":3078,"conditions":3079,"interventions":3081},"NCT00483314","Homocystinuria: Treatment With N-Acetylcysteine",[91],"2008-12","2009-02","2007-11",5,[3080],"Homocystinuria",[3063],{"trials":3083,"activeCount":102},[],{"trials":3085,"activeCount":102},[],{"trials":3087,"activeCount":102},[],{"intervention":3089,"totalTrials":138,"cells":3090},"Allogeneic Wharton's jelly-MSCs",{"EARLY_PHASE1":3091,"PHASE1":3093,"PHASE2":3095,"PHASE3":3106,"PHASE4":3108,"NA":3110},{"trials":3092,"activeCount":102},[],{"trials":3094,"activeCount":102},[],{"trials":3096,"activeCount":102},[3097],{"nctId":3098,"briefTitle":3099,"status":1077,"phases":3100,"primaryCompletion":3101,"completion":3101,"start":3102,"enrollment":3103,"conditions":3104,"interventions":3105},"NCT04869397","Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells",[91],"2023-05-26","2021-06-14",19,[2236],[3089],{"trials":3107,"activeCount":102},[],{"trials":3109,"activeCount":102},[],{"trials":3111,"activeCount":102},[],{"intervention":3113,"totalTrials":138,"cells":3114},"Somatotropin",{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3130,"PHASE4":3132,"NA":3134},{"trials":3116,"activeCount":102},[],{"trials":3118,"activeCount":102},[],{"trials":3120,"activeCount":102},[3121],{"nctId":3122,"briefTitle":3123,"status":464,"phases":3124,"primaryCompletion":3125,"completion":1238,"start":2471,"enrollment":1055,"conditions":3126,"interventions":3129},"NCT03091374","Impact of Recombinant Human Growth Hormone on HIV Persistence",[91],"2021-03",[3127,3128],"Human Immunodeficiency Virus","Growth Hormone Treatment",[3113],{"trials":3131,"activeCount":102},[],{"trials":3133,"activeCount":102},[],{"trials":3135,"activeCount":102},[],{"intervention":3137,"totalTrials":138,"cells":3138},"mDCF + Avelumab",{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3155,"PHASE4":3157,"NA":3159},{"trials":3140,"activeCount":102},[],{"trials":3142,"activeCount":102},[],{"trials":3144,"activeCount":102},[3145],{"nctId":3146,"briefTitle":3147,"status":112,"phases":3148,"primaryCompletion":3149,"completion":3150,"start":3151,"enrollment":3152,"conditions":3153,"interventions":3154},"NCT03288350","mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)",[91],"2020-12","2023-12","2018-02-22",55,[3053,3054],[3137],{"trials":3156,"activeCount":102},[],{"trials":3158,"activeCount":102},[],{"trials":3160,"activeCount":102},[],{"intervention":3162,"totalTrials":138,"cells":3163},"Taxotere, Cisplatin, and 5-FU",{"EARLY_PHASE1":3164,"PHASE1":3166,"PHASE2":3168,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3165,"activeCount":102},[],{"trials":3167,"activeCount":102},[],{"trials":3169,"activeCount":102},[3170],{"nctId":3171,"briefTitle":3172,"status":112,"phases":3173,"primaryCompletion":3174,"start":2281,"enrollment":969,"conditions":3175,"interventions":3178},"NCT00763646","Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma",[91],"2010-12",[3176,3177],"Gastric Junction Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[3162],{"trials":3180,"activeCount":102},[],{"trials":3182,"activeCount":102},[],{"trials":3184,"activeCount":102},[],{"intervention":3186,"totalTrials":138,"cells":3187},"Raltegravir",{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3189,"activeCount":102},[],{"trials":3191,"activeCount":102},[],{"trials":3193,"activeCount":102},[3194],{"nctId":3195,"briefTitle":3196,"status":464,"phases":3197,"primaryCompletion":3198,"completion":1054,"start":3199,"enrollment":3200,"conditions":3201,"interventions":3204},"NCT01231685","Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection",[91],"2016-03","2011-12",9,[36,3202,3203],"Hepatitis C","Liver Fibrosis",[3186,3205],"Ritonavir-boosted protease inhibitor",{"trials":3207,"activeCount":102},[],{"trials":3209,"activeCount":102},[],{"trials":3211,"activeCount":102},[],{"intervention":3205,"totalTrials":138,"cells":3213},{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3224,"PHASE4":3226,"NA":3228},{"trials":3215,"activeCount":102},[],{"trials":3217,"activeCount":102},[],{"trials":3219,"activeCount":102},[3220],{"nctId":3195,"briefTitle":3196,"status":464,"phases":3221,"primaryCompletion":3198,"completion":1054,"start":3199,"enrollment":3200,"conditions":3222,"interventions":3223},[91],[36,3202,3203],[3186,3205],{"trials":3225,"activeCount":102},[],{"trials":3227,"activeCount":102},[],{"trials":3229,"activeCount":102},[],{"intervention":3231,"totalTrials":138,"cells":3232},"AVR118",{"EARLY_PHASE1":3233,"PHASE1":3235,"PHASE2":3237,"PHASE3":3247,"PHASE4":3249,"NA":3251},{"trials":3234,"activeCount":102},[],{"trials":3236,"activeCount":102},[],{"trials":3238,"activeCount":102},[3239],{"nctId":3240,"briefTitle":3241,"status":1077,"phases":3242,"primaryCompletion":3243,"completion":3243,"start":3244,"enrollment":969,"conditions":3245,"interventions":3246},"NCT00765466","A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies",[91],"2010-05","2007-10",[2643],[3231],{"trials":3248,"activeCount":102},[],{"trials":3250,"activeCount":102},[],{"trials":3252,"activeCount":102},[],{"intervention":3254,"totalTrials":138,"cells":3255},"Sorafenib and Vinorelbine",{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3269,"PHASE4":3271,"NA":3273},{"trials":3257,"activeCount":102},[],{"trials":3259,"activeCount":102},[],{"trials":3261,"activeCount":102},[3262],{"nctId":3263,"briefTitle":3264,"status":112,"phases":3265,"primaryCompletion":3174,"completion":3199,"start":3244,"enrollment":753,"conditions":3266,"interventions":3268},"NCT00764972","Phase IB\u002FII Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer",[90,91],[3267],"Metastatic Breast Cancer",[3254],{"trials":3270,"activeCount":102},[],{"trials":3272,"activeCount":102},[],{"trials":3274,"activeCount":102},[],{"intervention":3276,"totalTrials":138,"cells":3277},"Enoxacin",{"EARLY_PHASE1":3278,"PHASE1":3280,"PHASE2":3282,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3279,"activeCount":102},[],{"trials":3281,"activeCount":102},[],{"trials":3283,"activeCount":102},[3284],{"nctId":3285,"briefTitle":3286,"status":464,"phases":3287,"primaryCompletion":3288,"completion":3288,"start":3289,"enrollment":29,"conditions":3290,"interventions":3292},"NCT04840823","Enoxacin for Amyotrophic Lateral Sclerosis (ALS)",[90,91],"2023-11-15","2021-03-26",[3291],"Amyotrophic Lateral Sclerosis",[3276],{"trials":3294,"activeCount":102},[],{"trials":3296,"activeCount":102},[],{"trials":3298,"activeCount":102},[],{"intervention":3300,"totalTrials":138,"cells":3301},"Ethosuximide",{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3306,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3303,"activeCount":102},[],{"trials":3305,"activeCount":102},[],{"trials":3307,"activeCount":102},[3308],{"nctId":3309,"briefTitle":3310,"status":1077,"phases":3311,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":437,"conditions":3314,"interventions":3316},"NCT00689585","Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)",[91],"2010-07","2008-09",[3315],"Complex Regional Pain Syndromes",[3300],{"trials":3318,"activeCount":102},[],{"trials":3320,"activeCount":102},[],{"trials":3322,"activeCount":102},[],{"intervention":3324,"totalTrials":138,"cells":3325},"Bupivacaine with 15 micrograms of fentanyl",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3339,"PHASE4":3341,"NA":3343},{"trials":3327,"activeCount":102},[],{"trials":3329,"activeCount":102},[],{"trials":3331,"activeCount":102},[3332],{"nctId":3333,"briefTitle":3334,"status":112,"phases":3335,"primaryCompletion":2943,"completion":2943,"start":1856,"enrollment":1789,"conditions":3336,"interventions":3338},"NCT01896960","ET50 With Fentanyl for Post Caesarean Section Spinal Hypotension",[91],[2969,3337],"Pregnancy",[3324],{"trials":3340,"activeCount":102},[],{"trials":3342,"activeCount":102},[],{"trials":3344,"activeCount":102},[],{"intervention":3346,"totalTrials":138,"cells":3347},"Atezolizumab",{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3352,"PHASE3":3364,"PHASE4":3366,"NA":3368},{"trials":3349,"activeCount":102},[],{"trials":3351,"activeCount":102},[],{"trials":3353,"activeCount":102},[3354],{"nctId":3355,"briefTitle":3356,"status":112,"phases":3357,"primaryCompletion":3358,"completion":3359,"start":3360,"enrollment":1597,"conditions":3361,"interventions":3363},"NCT03620435","Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer",[91],"2020-05-30","2020-12-30","2018-05-01",[3362],"Safety Issues",[3346],{"trials":3365,"activeCount":102},[],{"trials":3367,"activeCount":102},[],{"trials":3369,"activeCount":102},[],{"intervention":3371,"totalTrials":138,"cells":3372},"Lactated Ringer's Solution",{"EARLY_PHASE1":3373,"PHASE1":3375,"PHASE2":3377,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3374,"activeCount":102},[],{"trials":3376,"activeCount":102},[],{"trials":3378,"activeCount":102},[3379],{"nctId":3380,"briefTitle":3381,"status":112,"phases":3382,"primaryCompletion":3383,"completion":3384,"start":3385,"enrollment":1095,"conditions":3386,"interventions":3389},"NCT01236833","Lactated Ringer's Solution in Neonates With Feeding Intolerance",[91],"2012-06","2012-09","2010-11",[3387,3388],"Intestinal Disease","Feeding Disorder Neonatal",[3371],{"trials":3391,"activeCount":102},[],{"trials":3393,"activeCount":102},[],{"trials":3395,"activeCount":102},[],{"intervention":3397,"totalTrials":138,"cells":3398},"Omalizumab",{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3414,"PHASE4":3416,"NA":3418},{"trials":3400,"activeCount":102},[],{"trials":3402,"activeCount":102},[],{"trials":3404,"activeCount":102},[3405],{"nctId":3406,"briefTitle":3407,"status":112,"phases":3408,"primaryCompletion":3409,"completion":3410,"start":3411,"enrollment":1789,"conditions":3412,"interventions":3413},"NCT04720612","COVID-19 Immunologic Antiviral Therapy With Omalizumab",[91],"2022-11-07","2022-12-16","2021-10-15",[2236],[3397],{"trials":3415,"activeCount":102},[],{"trials":3417,"activeCount":102},[],{"trials":3419,"activeCount":102},[],{"intervention":3421,"totalTrials":138,"cells":3422},"27-hour inpatient intervention",{"EARLY_PHASE1":3423,"PHASE1":3425,"PHASE2":3427,"PHASE3":3437,"PHASE4":3439,"NA":3441},{"trials":3424,"activeCount":102},[],{"trials":3426,"activeCount":102},[],{"trials":3428,"activeCount":102},[3429],{"nctId":3430,"briefTitle":3431,"status":464,"phases":3432,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":1217,"conditions":3435,"interventions":3436},"NCT03800875","Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting",[91],"2020-09-19","2019-02-08",[22],[3421],{"trials":3438,"activeCount":102},[],{"trials":3440,"activeCount":102},[],{"trials":3442,"activeCount":102},[],{"intervention":3444,"totalTrials":138,"cells":3445},"Yttrium 90 Ibritumomab Tiuxetan",{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3460,"PHASE4":3462,"NA":3464},{"trials":3447,"activeCount":102},[],{"trials":3449,"activeCount":102},[],{"trials":3451,"activeCount":102},[3452],{"nctId":3453,"briefTitle":3454,"status":112,"phases":3455,"start":3456,"enrollment":1789,"conditions":3457,"interventions":3459},"NCT00438581","Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma",[91],"2007-03",[3458],"Non-Hodgkin's Lymphoma",[3444],{"trials":3461,"activeCount":102},[],{"trials":3463,"activeCount":102},[],{"trials":3465,"activeCount":102},[],{"intervention":3467,"totalTrials":138,"cells":3468},"Propranolol PO",{"EARLY_PHASE1":3469,"PHASE1":3471,"PHASE2":3473,"PHASE3":3486,"PHASE4":3488,"NA":3490},{"trials":3470,"activeCount":102},[],{"trials":3472,"activeCount":102},[],{"trials":3474,"activeCount":102},[3475],{"nctId":3476,"briefTitle":3477,"status":1077,"phases":3478,"primaryCompletion":3479,"completion":3479,"start":3480,"enrollment":26,"conditions":3481,"interventions":3483},"NCT02511483","Genetic Predictors of Analgesic Efficacy of Propranolol for Treating Postoperative Pain",[91],"2016-11-12","2015-05-18",[3482],"Postoperative Pain",[3467,3484,3485],"IV-PCA morphine","COMT-haplotypes",{"trials":3487,"activeCount":102},[],{"trials":3489,"activeCount":102},[],{"trials":3491,"activeCount":102},[],{"intervention":3484,"totalTrials":138,"cells":3493},{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3504,"PHASE4":3506,"NA":3508},{"trials":3495,"activeCount":102},[],{"trials":3497,"activeCount":102},[],{"trials":3499,"activeCount":102},[3500],{"nctId":3476,"briefTitle":3477,"status":1077,"phases":3501,"primaryCompletion":3479,"completion":3479,"start":3480,"enrollment":26,"conditions":3502,"interventions":3503},[91],[3482],[3467,3484,3485],{"trials":3505,"activeCount":102},[],{"trials":3507,"activeCount":102},[],{"trials":3509,"activeCount":102},[],{"intervention":3485,"totalTrials":138,"cells":3511},{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3516,"PHASE3":3522,"PHASE4":3524,"NA":3526},{"trials":3513,"activeCount":102},[],{"trials":3515,"activeCount":102},[],{"trials":3517,"activeCount":102},[3518],{"nctId":3476,"briefTitle":3477,"status":1077,"phases":3519,"primaryCompletion":3479,"completion":3479,"start":3480,"enrollment":26,"conditions":3520,"interventions":3521},[91],[3482],[3467,3484,3485],{"trials":3523,"activeCount":102},[],{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[],{"intervention":542,"totalTrials":138,"cells":3529},{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3540,"PHASE4":3542,"NA":3544},{"trials":3531,"activeCount":102},[],{"trials":3533,"activeCount":102},[],{"trials":3535,"activeCount":102},[3536],{"nctId":531,"briefTitle":532,"status":464,"phases":3537,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":3538,"interventions":3539},[91],[539],[541,542,543],{"trials":3541,"activeCount":102},[],{"trials":3543,"activeCount":102},[],{"trials":3545,"activeCount":102},[],{"intervention":543,"totalTrials":138,"cells":3547},{"EARLY_PHASE1":3548,"PHASE1":3550,"PHASE2":3552,"PHASE3":3558,"PHASE4":3560,"NA":3562},{"trials":3549,"activeCount":102},[],{"trials":3551,"activeCount":102},[],{"trials":3553,"activeCount":102},[3554],{"nctId":531,"briefTitle":532,"status":464,"phases":3555,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":3556,"interventions":3557},[91],[539],[541,542,543],{"trials":3559,"activeCount":102},[],{"trials":3561,"activeCount":102},[],{"trials":3563,"activeCount":102},[],{"intervention":3565,"totalTrials":138,"cells":3566},"Hybrid automated Lyumjev delivery system with carbohydrate counting",{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3582,"PHASE4":3584,"NA":3586},{"trials":3568,"activeCount":102},[],{"trials":3570,"activeCount":102},[],{"trials":3572,"activeCount":102},[3573],{"nctId":3574,"briefTitle":3575,"status":112,"phases":3576,"primaryCompletion":1238,"completion":1238,"start":3577,"enrollment":2944,"conditions":3578,"interventions":3579},"NCT06021158","A Trial to Compare Automated Lyumjev Delivery With Carbohydrate Counting, Qualitative Meal-size Estimation, and Meal Detection in Type 1 Diabetes",[91],"2023-12-20",[22,19],[3565,3580,3581],"Hybrid automated Lyumjev delivery system with meal size estimation","Fully automated Lyumjev delivery system with meal detection",{"trials":3583,"activeCount":102},[],{"trials":3585,"activeCount":102},[],{"trials":3587,"activeCount":102},[],{"intervention":3580,"totalTrials":138,"cells":3589},{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3600,"PHASE4":3602,"NA":3604},{"trials":3591,"activeCount":102},[],{"trials":3593,"activeCount":102},[],{"trials":3595,"activeCount":102},[3596],{"nctId":3574,"briefTitle":3575,"status":112,"phases":3597,"primaryCompletion":1238,"completion":1238,"start":3577,"enrollment":2944,"conditions":3598,"interventions":3599},[91],[22,19],[3565,3580,3581],{"trials":3601,"activeCount":102},[],{"trials":3603,"activeCount":102},[],{"trials":3605,"activeCount":102},[],{"intervention":3581,"totalTrials":138,"cells":3607},{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3612,"PHASE3":3618,"PHASE4":3620,"NA":3622},{"trials":3609,"activeCount":102},[],{"trials":3611,"activeCount":102},[],{"trials":3613,"activeCount":102},[3614],{"nctId":3574,"briefTitle":3575,"status":112,"phases":3615,"primaryCompletion":1238,"completion":1238,"start":3577,"enrollment":2944,"conditions":3616,"interventions":3617},[91],[22,19],[3565,3580,3581],{"trials":3619,"activeCount":102},[],{"trials":3621,"activeCount":102},[],{"trials":3623,"activeCount":102},[],{"intervention":3625,"totalTrials":138,"cells":3626},"Niacin",{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3628,"activeCount":102},[],{"trials":3630,"activeCount":102},[],{"trials":3632,"activeCount":102},[3633],{"nctId":3634,"briefTitle":3635,"status":464,"phases":3636,"primaryCompletion":449,"completion":449,"start":2693,"enrollment":3637,"conditions":3638,"interventions":3639},"NCT02018965","Niacin on Immune Activation : a Proof-of-concept Study",[91],16,[36],[3625,3625],{"trials":3641,"activeCount":102},[],{"trials":3643,"activeCount":102},[],{"trials":3645,"activeCount":102},[],{"intervention":3647,"totalTrials":138,"cells":3648},"0.75% Ropivacaine",{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3664,"PHASE4":3666,"NA":3668},{"trials":3650,"activeCount":102},[],{"trials":3652,"activeCount":102},[],{"trials":3654,"activeCount":102},[3655],{"nctId":3656,"briefTitle":3657,"status":464,"phases":3658,"primaryCompletion":3659,"completion":3659,"start":1569,"enrollment":2472,"conditions":3660,"interventions":3662},"NCT02270255","Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization",[91],"2017-11-01",[3661],"Leiomyoma",[3647,3663],"1% Xylocaine",{"trials":3665,"activeCount":102},[],{"trials":3667,"activeCount":102},[],{"trials":3669,"activeCount":102},[],{"intervention":3663,"totalTrials":138,"cells":3671},{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3676,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3673,"activeCount":102},[],{"trials":3675,"activeCount":102},[],{"trials":3677,"activeCount":102},[3678],{"nctId":3656,"briefTitle":3657,"status":464,"phases":3679,"primaryCompletion":3659,"completion":3659,"start":1569,"enrollment":2472,"conditions":3680,"interventions":3681},[91],[3661],[3647,3663],{"trials":3683,"activeCount":102},[],{"trials":3685,"activeCount":102},[],{"trials":3687,"activeCount":102},[],{"intervention":3689,"totalTrials":138,"cells":3690},"Spinal analgesia",{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3692,"activeCount":102},[],{"trials":3694,"activeCount":102},[],{"trials":3696,"activeCount":102},[3697],{"nctId":3698,"briefTitle":3699,"status":464,"phases":3700,"primaryCompletion":1359,"completion":1359,"start":1545,"enrollment":1789,"conditions":3701,"interventions":3705},"NCT01477190","Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program",[90,91],[3702,3703,3704],"Colon Cancer","Inflammatory Bowel Diseases","Diverticulitis",[3689,3706],"Patient Control Analgesia (PCA) Morphine",{"trials":3708,"activeCount":102},[],{"trials":3710,"activeCount":102},[],{"trials":3712,"activeCount":102},[],{"intervention":3706,"totalTrials":138,"cells":3714},{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3719,"PHASE3":3725,"PHASE4":3727,"NA":3729},{"trials":3716,"activeCount":102},[],{"trials":3718,"activeCount":102},[],{"trials":3720,"activeCount":102},[3721],{"nctId":3698,"briefTitle":3699,"status":464,"phases":3722,"primaryCompletion":1359,"completion":1359,"start":1545,"enrollment":1789,"conditions":3723,"interventions":3724},[90,91],[3702,3703,3704],[3689,3706],{"trials":3726,"activeCount":102},[],{"trials":3728,"activeCount":102},[],{"trials":3730,"activeCount":102},[],{"intervention":3732,"totalTrials":138,"cells":3733},"Pembrolizumab",{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3752,"PHASE4":3754,"NA":3756},{"trials":3735,"activeCount":102},[],{"trials":3737,"activeCount":102},[],{"trials":3739,"activeCount":102},[3740],{"nctId":3741,"briefTitle":3742,"status":1077,"phases":3743,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":1714,"conditions":3746,"interventions":3748},"NCT04638582","Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)",[91],"2026-04-14","2022-08-28",[3747],"Lung Cancer, Nonsmall Cell",[3732,3749,3750,3751],"Carboplatin","Paclitaxel","Pemetrexed",{"trials":3753,"activeCount":102},[],{"trials":3755,"activeCount":102},[],{"trials":3757,"activeCount":102},[],{"intervention":3749,"totalTrials":138,"cells":3759},{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3764,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3761,"activeCount":102},[],{"trials":3763,"activeCount":102},[],{"trials":3765,"activeCount":102},[3766],{"nctId":3741,"briefTitle":3742,"status":1077,"phases":3767,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":1714,"conditions":3768,"interventions":3769},[91],[3747],[3732,3749,3750,3751],{"trials":3771,"activeCount":102},[],{"trials":3773,"activeCount":102},[],{"trials":3775,"activeCount":102},[],{"intervention":3750,"totalTrials":138,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3779,"activeCount":102},[],{"trials":3781,"activeCount":102},[],{"trials":3783,"activeCount":102},[3784],{"nctId":3741,"briefTitle":3742,"status":1077,"phases":3785,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":1714,"conditions":3786,"interventions":3787},[91],[3747],[3732,3749,3750,3751],{"trials":3789,"activeCount":102},[],{"trials":3791,"activeCount":102},[],{"trials":3793,"activeCount":102},[],{"intervention":3751,"totalTrials":138,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3797,"activeCount":102},[],{"trials":3799,"activeCount":102},[],{"trials":3801,"activeCount":102},[3802],{"nctId":3741,"briefTitle":3742,"status":1077,"phases":3803,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":1714,"conditions":3804,"interventions":3805},[91],[3747],[3732,3749,3750,3751],{"trials":3807,"activeCount":102},[],{"trials":3809,"activeCount":102},[],{"trials":3811,"activeCount":102},[],{"intervention":3813,"totalTrials":138,"cells":3814},"AGS-004",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3831,"PHASE4":3833,"NA":3835},{"trials":3816,"activeCount":102},[],{"trials":3818,"activeCount":102},[],{"trials":3820,"activeCount":102},[3821],{"nctId":3822,"briefTitle":3823,"status":464,"phases":3824,"primaryCompletion":3825,"completion":2496,"start":3826,"enrollment":26,"conditions":3827,"interventions":3830},"NCT00381212","A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.",[90,91],"2008-02","2006-09",[3828,3829],"HIV Seropositivity","Acquired Immunodeficiency Syndrome",[3813],{"trials":3832,"activeCount":102},[],{"trials":3834,"activeCount":102},[],{"trials":3836,"activeCount":102},[],{"intervention":3838,"totalTrials":138,"cells":3839},"Cannabis",{"EARLY_PHASE1":3840,"PHASE1":3842,"PHASE2":3844,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3841,"activeCount":102},[],{"trials":3843,"activeCount":102},[],{"trials":3845,"activeCount":102},[3846],{"nctId":3847,"briefTitle":3848,"status":112,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3637,"conditions":3853,"interventions":3857},"NCT03060993","CAN BREATHE in COPD Trial",[91],"2018-01-01","2018-04-30","2017-03-01",[3854,3855,3856],"Chronic Obstructive Pulmonary Disease (COPD)","Breathlessness","Exercise Intolerance",[3838],{"trials":3859,"activeCount":102},[],{"trials":3861,"activeCount":102},[],{"trials":3863,"activeCount":102},[],{"intervention":3865,"totalTrials":138,"cells":3866},"Tazarotene",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3868,"activeCount":102},[],{"trials":3870,"activeCount":102},[],{"trials":3872,"activeCount":102},[3873],{"nctId":3874,"briefTitle":3875,"status":112,"phases":3876,"primaryCompletion":3199,"completion":2182,"start":3877,"enrollment":17,"conditions":3878,"interventions":3880},"NCT00779896","Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study",[90,91],"2008-10",[3879],"Cutaneous T-Cell Lymphoma",[3865],{"trials":3882,"activeCount":102},[],{"trials":3884,"activeCount":102},[],{"trials":3886,"activeCount":102},[],{"intervention":3888,"totalTrials":138,"cells":3889},"Ringer's Lactate",{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3904,"PHASE4":3906,"NA":3908},{"trials":3891,"activeCount":102},[],{"trials":3893,"activeCount":102},[],{"trials":3895,"activeCount":102},[3896],{"nctId":3897,"briefTitle":3898,"status":112,"phases":3899,"primaryCompletion":3900,"start":2593,"enrollment":1240,"conditions":3901,"interventions":3903},"NCT01108601","Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity",[90,91],"2011-04",[3902],"Hearing Loss",[3888],{"trials":3905,"activeCount":102},[],{"trials":3907,"activeCount":102},[],{"trials":3909,"activeCount":102},[],{"intervention":3911,"totalTrials":138,"cells":3912},"rhDNase I",{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3927,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3914,"activeCount":102},[],{"trials":3916,"activeCount":102},[3917],{"nctId":3918,"briefTitle":3919,"status":464,"phases":3920,"primaryCompletion":3921,"completion":3922,"start":3923,"enrollment":17,"conditions":3924,"interventions":3926},"NCT04409925","DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)",[90],"2021-04-01","2021-08-01","2020-12-25",[3925],"COVID-19 Infection",[3911],{"trials":3928,"activeCount":102},[],{"trials":3930,"activeCount":102},[],{"trials":3932,"activeCount":102},[],{"trials":3934,"activeCount":102},[],{"intervention":3936,"totalTrials":138,"cells":3937},"Sildenafil",{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3952,"PHASE3":3954,"PHASE4":3956,"NA":3958},{"trials":3939,"activeCount":102},[],{"trials":3941,"activeCount":102},[3942],{"nctId":3943,"briefTitle":3944,"status":464,"phases":3945,"primaryCompletion":3946,"completion":2305,"start":3947,"enrollment":2855,"conditions":3948,"interventions":3950},"NCT02812433","Sildenafil Administration to Treat Neonatal Encephalopathy",[90],"2019-01","2016-07",[3949],"Neonatal Encephalopathy",[3936,3951],"Ora-Blend",{"trials":3953,"activeCount":102},[],{"trials":3955,"activeCount":102},[],{"trials":3957,"activeCount":102},[],{"trials":3959,"activeCount":102},[],{"intervention":3951,"totalTrials":138,"cells":3961},{"EARLY_PHASE1":3962,"PHASE1":3964,"PHASE2":3970,"PHASE3":3972,"PHASE4":3974,"NA":3976},{"trials":3963,"activeCount":102},[],{"trials":3965,"activeCount":102},[3966],{"nctId":3943,"briefTitle":3944,"status":464,"phases":3967,"primaryCompletion":3946,"completion":2305,"start":3947,"enrollment":2855,"conditions":3968,"interventions":3969},[90],[3949],[3936,3951],{"trials":3971,"activeCount":102},[],{"trials":3973,"activeCount":102},[],{"trials":3975,"activeCount":102},[],{"trials":3977,"activeCount":102},[],{"intervention":3979,"totalTrials":138,"cells":3980},"Furosemide",{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3992,"PHASE3":3994,"PHASE4":3996,"NA":3998},{"trials":3982,"activeCount":102},[],{"trials":3984,"activeCount":102},[3985],{"nctId":3986,"briefTitle":3987,"status":112,"phases":3988,"primaryCompletion":2115,"completion":3989,"start":2167,"enrollment":969,"conditions":3990,"interventions":3991},"NCT01851980","Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness",[90],"2017-09",[3855],[3979],{"trials":3993,"activeCount":102},[],{"trials":3995,"activeCount":102},[],{"trials":3997,"activeCount":102},[],{"trials":3999,"activeCount":102},[],{"intervention":4001,"totalTrials":138,"cells":4002},"Temozolomide",{"EARLY_PHASE1":4003,"PHASE1":4005,"PHASE2":4017,"PHASE3":4019,"PHASE4":4021,"NA":4023},{"trials":4004,"activeCount":102},[],{"trials":4006,"activeCount":102},[4007],{"nctId":4008,"briefTitle":4009,"status":2258,"phases":4010,"primaryCompletion":4011,"completion":4012,"start":4013,"enrollment":102,"conditions":4014,"interventions":4016},"NCT03480867","Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)",[90],"2021-06","2023-11","2017-03",[4015],"Glioblastoma Multiforme, Adult",[4001],{"trials":4018,"activeCount":102},[],{"trials":4020,"activeCount":102},[],{"trials":4022,"activeCount":102},[],{"trials":4024,"activeCount":102},[],{"intervention":4026,"totalTrials":138,"cells":4027},"14-day outpatient intervention",{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4041,"PHASE3":4043,"PHASE4":4045,"NA":4047},{"trials":4029,"activeCount":102},[],{"trials":4031,"activeCount":102},[4032],{"nctId":4033,"briefTitle":4034,"status":464,"phases":4035,"primaryCompletion":4036,"completion":4037,"start":4038,"enrollment":1597,"conditions":4039,"interventions":4040},"NCT04450563","Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System",[90],"2022-01-05","2022-01-13","2020-11-02",[19],[4026],{"trials":4042,"activeCount":102},[],{"trials":4044,"activeCount":102},[],{"trials":4046,"activeCount":102},[],{"trials":4048,"activeCount":102},[],{"intervention":4050,"totalTrials":138,"cells":4051},"Camu Camu",{"EARLY_PHASE1":4052,"PHASE1":4054,"PHASE2":4064,"PHASE3":4066,"PHASE4":4068,"NA":4070},{"trials":4053,"activeCount":102},[],{"trials":4055,"activeCount":102},[4056],{"nctId":4057,"briefTitle":4058,"status":464,"phases":4059,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":1055,"conditions":4062,"interventions":4063},"NCT04058392","Camu Camu in ART-treated People Living with HIV",[90],"2022-07-20","2020-11-09",[28],[4050],{"trials":4065,"activeCount":102},[],{"trials":4067,"activeCount":102},[],{"trials":4069,"activeCount":102},[],{"trials":4071,"activeCount":102},[],{"intervention":4073,"totalTrials":138,"cells":4074},"Fentanyl Citrate",{"EARLY_PHASE1":4075,"PHASE1":4086,"PHASE2":4088,"PHASE3":4090,"PHASE4":4092,"NA":4094},{"trials":4076,"activeCount":102},[4077],{"nctId":4078,"briefTitle":4079,"status":464,"phases":4080,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":20,"conditions":4083,"interventions":4085},"NCT01853449","Inhaled Fentanyl Citrate & Dyspnea",[89],"2014-08","2013-06",[4084],"Dyspnea",[4073],{"trials":4087,"activeCount":102},[],{"trials":4089,"activeCount":102},[],{"trials":4091,"activeCount":102},[],{"trials":4093,"activeCount":102},[],{"trials":4095,"activeCount":102},[],{"intervention":4097,"totalTrials":138,"cells":4098},"Doxepin and Zopiclone",{"EARLY_PHASE1":4099,"PHASE1":4109,"PHASE2":4111,"PHASE3":4113,"PHASE4":4115,"NA":4117},{"trials":4100,"activeCount":102},[4101],{"nctId":4102,"briefTitle":4103,"status":464,"phases":4104,"primaryCompletion":2182,"completion":2182,"start":4105,"enrollment":1240,"conditions":4106,"interventions":4108},"NCT01489982","Treatments for Insomnia in Patients With Parkinson's Disease",[89],"2011-01",[2024,4107],"Insomnia",[4097],{"trials":4110,"activeCount":102},[],{"trials":4112,"activeCount":102},[],{"trials":4114,"activeCount":102},[],{"trials":4116,"activeCount":102},[],{"trials":4118,"activeCount":102},[],{"intervention":4120,"totalTrials":138,"cells":4121},"Ondansetron",{"EARLY_PHASE1":4122,"PHASE1":4132,"PHASE2":4134,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4123,"activeCount":102},[4124],{"nctId":4125,"briefTitle":4126,"status":464,"phases":4127,"primaryCompletion":4128,"completion":4129,"start":4082,"enrollment":969,"conditions":4130,"interventions":4131},"NCT01851993","Inhaled Ondansetron & Dyspnea",[89],"2014-09","2014-12",[4084],[4120],{"trials":4133,"activeCount":102},[],{"trials":4135,"activeCount":102},[],{"trials":4137,"activeCount":102},[],{"trials":4139,"activeCount":102},[],{"trials":4141,"activeCount":102},[],{"intervention":4143,"totalTrials":437,"cells":4144},"Lidocaine",{"EARLY_PHASE1":4145,"PHASE1":4147,"PHASE2":4149,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[],{"trials":4150,"activeCount":102},[4151],{"nctId":4152,"briefTitle":4153,"status":464,"phases":4154,"primaryCompletion":1359,"completion":1359,"start":4155,"enrollment":1095,"conditions":4156,"interventions":4157},"NCT01155440","Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine",[91],"2009-06",[3702,3703,3704],[4143],{"trials":4159,"activeCount":102},[],{"trials":4161,"activeCount":102},[],{"trials":4163,"activeCount":102},[4164,4173,4183],{"nctId":4165,"briefTitle":4166,"status":464,"phases":4167,"primaryCompletion":4168,"completion":4168,"start":4168,"enrollment":1978,"conditions":4169,"interventions":4171},"NCT01062906","Intravenous Lidocaine for Laparoscopic Cholecystectomy",[94],"2010-03",[3482,4170],"Opioid Consumption",[4143,4172],"Fentanyl",{"nctId":4174,"briefTitle":4175,"status":464,"phases":4176,"primaryCompletion":4177,"completion":4178,"start":4179,"enrollment":1095,"conditions":4180,"interventions":4181},"NCT00982618","Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine",[94],"2010-06","2011-06","2009-07",[3702,3703,3704],[4143,4182],"PCA Morphine",{"nctId":4184,"briefTitle":4185,"status":112,"phases":4186,"primaryCompletion":4187,"completion":4187,"start":4188,"enrollment":2307,"conditions":4189,"interventions":4192},"NCT03862287","Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine",[94],"2019-12","2018-11-01",[4190,4191],"Orthopedic Disorder","Leg Injuries",[4143,4193],"Bupivacaine Hcl 0.5% Inj_#2",{"intervention":4195,"totalTrials":1042,"cells":4196},"Insulin",{"EARLY_PHASE1":4197,"PHASE1":4199,"PHASE2":4201,"PHASE3":4203,"PHASE4":4205,"NA":4215},{"trials":4198,"activeCount":102},[],{"trials":4200,"activeCount":102},[],{"trials":4202,"activeCount":102},[],{"trials":4204,"activeCount":102},[],{"trials":4206,"activeCount":102},[4207],{"nctId":4208,"briefTitle":4209,"status":112,"phases":4210,"primaryCompletion":4211,"completion":4211,"start":2692,"enrollment":1217,"conditions":4212,"interventions":4214},"NCT02032953","Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia",[93],"2024-04",[4213],"Colorectal Cancer",[4195],{"trials":4216,"activeCount":102},[4217,4224],{"nctId":4218,"briefTitle":4219,"status":112,"phases":4220,"primaryCompletion":3946,"completion":3946,"start":4221,"enrollment":1240,"conditions":4222,"interventions":4223},"NCT03349489","Insulin-based Strategies to Prevent Hypoglycemia During Exercise",[94],"2018-05-18",[683],[4195],{"nctId":4225,"briefTitle":4226,"status":112,"phases":4227,"primaryCompletion":2692,"completion":4228,"start":4105,"enrollment":3078,"conditions":4229,"interventions":4231},"NCT01271140","High Dose Insulin Therapy to Improve Liver Function",[94],"2014-06",[4230],"Hepatitis C Virus",[4195],{"intervention":4233,"totalTrials":98,"cells":4234},"Fiasp",{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4241,"PHASE4":4243,"NA":4245},{"trials":4236,"activeCount":102},[],{"trials":4238,"activeCount":102},[],{"trials":4240,"activeCount":102},[],{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[],{"trials":4246,"activeCount":102},[4247,4256],{"nctId":4248,"briefTitle":4249,"status":464,"phases":4250,"primaryCompletion":4251,"completion":4251,"start":4252,"enrollment":2944,"conditions":4253,"interventions":4254},"NCT05199714","A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes",[94],"2023-03-25","2022-02-21",[19],[4233,2900,4255],"Aspart",{"nctId":4257,"briefTitle":4258,"status":464,"phases":4259,"primaryCompletion":4260,"completion":4260,"start":4261,"enrollment":753,"conditions":4262,"interventions":4264},"NCT04163874","Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas",[94],"2022-01-30","2020-02-14",[19,683,4263],"Hyperglycemia, Postprandial",[4233,4265],"Pramlintide Acetate",{"intervention":2900,"totalTrials":98,"cells":4267},{"EARLY_PHASE1":4268,"PHASE1":4270,"PHASE2":4272,"PHASE3":4274,"PHASE4":4280,"NA":4282},{"trials":4269,"activeCount":102},[],{"trials":4271,"activeCount":102},[],{"trials":4273,"activeCount":102},[],{"trials":4275,"activeCount":102},[4276],{"nctId":2892,"briefTitle":2893,"status":112,"phases":4277,"primaryCompletion":752,"completion":2895,"start":2896,"enrollment":969,"conditions":4278,"interventions":4279},[91,92],[2898,22],[2900,2881],{"trials":4281,"activeCount":102},[],{"trials":4283,"activeCount":102},[4284],{"nctId":4248,"briefTitle":4249,"status":464,"phases":4285,"primaryCompletion":4251,"completion":4251,"start":4252,"enrollment":2944,"conditions":4286,"interventions":4287},[94],[19],[4233,2900,4255],{"intervention":472,"totalTrials":98,"cells":4289},{"EARLY_PHASE1":4290,"PHASE1":4292,"PHASE2":4294,"PHASE3":4296,"PHASE4":4298,"NA":4304},{"trials":4291,"activeCount":102},[],{"trials":4293,"activeCount":102},[],{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[],{"trials":4299,"activeCount":102},[4300],{"nctId":462,"briefTitle":463,"status":464,"phases":4301,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":4302,"interventions":4303},[93],[470],[472,436],{"trials":4305,"activeCount":102},[4306],{"nctId":489,"briefTitle":490,"status":464,"phases":4307,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":4308,"interventions":4309},[94],[496,497],[472,484,436],{"intervention":4311,"totalTrials":98,"cells":4312},"Vitamin D",{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4327,"PHASE4":4329,"NA":4331},{"trials":4314,"activeCount":102},[],{"trials":4316,"activeCount":102},[],{"trials":4318,"activeCount":102},[4319],{"nctId":4320,"briefTitle":4321,"status":464,"phases":4322,"primaryCompletion":1857,"completion":3199,"start":3456,"enrollment":4323,"conditions":4324,"interventions":4326},"NCT00381914","Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants",[91],132,[4325],"Vitamin D Deficiency",[4311,4311,4311],{"trials":4328,"activeCount":102},[],{"trials":4330,"activeCount":102},[],{"trials":4332,"activeCount":102},[4333],{"nctId":4334,"briefTitle":4335,"status":2258,"phases":4336,"primaryCompletion":4337,"completion":4337,"start":1545,"enrollment":102,"conditions":4338,"interventions":4340},"NCT01400009","Vitamin D Replacement in Statin-Induced Myopathy",[94],"2012-07",[4339],"HMG COA Reductase Inhibitor Adverse Reaction",[4311],{"intervention":4265,"totalTrials":98,"cells":4342},{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4349,"PHASE4":4351,"NA":4353},{"trials":4344,"activeCount":102},[],{"trials":4346,"activeCount":102},[],{"trials":4348,"activeCount":102},[],{"trials":4350,"activeCount":102},[],{"trials":4352,"activeCount":102},[],{"trials":4354,"activeCount":102},[4355,4359],{"nctId":4257,"briefTitle":4258,"status":464,"phases":4356,"primaryCompletion":4260,"completion":4260,"start":4261,"enrollment":753,"conditions":4357,"interventions":4358},[94],[19,683,4263],[4233,4265],{"nctId":4360,"briefTitle":4361,"status":112,"phases":4362,"primaryCompletion":4211,"completion":4211,"start":4363,"enrollment":655,"conditions":4364,"interventions":4366},"NCT04243629","Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes",[94],"2021-11-12",[22,19,4365],"Postprandial Hyperglycemia",[4367,4265],"Rapid-Acting Insulin",{"intervention":4369,"totalTrials":138,"cells":4370},"Temozolomide and Accelerated Hypofractionation RT",{"EARLY_PHASE1":4371,"PHASE1":4373,"PHASE2":4375,"PHASE3":4377,"PHASE4":4379,"NA":4381},{"trials":4372,"activeCount":102},[],{"trials":4374,"activeCount":102},[],{"trials":4376,"activeCount":102},[],{"trials":4378,"activeCount":102},[],{"trials":4380,"activeCount":102},[],{"trials":4382,"activeCount":102},[4383],{"nctId":4384,"briefTitle":4385,"status":464,"phases":4386,"primaryCompletion":4129,"completion":4129,"start":3075,"enrollment":12,"conditions":4387,"interventions":4389},"NCT01702610","Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme",[94],[4388],"Glioblastoma Mutliforme",[4369],{"intervention":4391,"totalTrials":138,"cells":4392},"Naltrexone",{"EARLY_PHASE1":4393,"PHASE1":4395,"PHASE2":4397,"PHASE3":4399,"PHASE4":4401,"NA":4403},{"trials":4394,"activeCount":102},[],{"trials":4396,"activeCount":102},[],{"trials":4398,"activeCount":102},[],{"trials":4400,"activeCount":102},[],{"trials":4402,"activeCount":102},[],{"trials":4404,"activeCount":102},[4405],{"nctId":4406,"briefTitle":4407,"status":464,"phases":4408,"primaryCompletion":4409,"completion":4409,"start":4410,"enrollment":228,"conditions":4411,"interventions":4413},"NCT04757506","An Investigation of the Effects of Opioid Receptor Blockade on Changes in Self-esteem and Social Attention",[94],"2013-03-15","2012-07-09",[4412],"Self Esteem",[4391],{"intervention":4415,"totalTrials":138,"cells":4416},"Continuous Adductor Canal Block",{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4423,"PHASE4":4425,"NA":4427},{"trials":4418,"activeCount":102},[],{"trials":4420,"activeCount":102},[],{"trials":4422,"activeCount":102},[],{"trials":4424,"activeCount":102},[],{"trials":4426,"activeCount":102},[],{"trials":4428,"activeCount":102},[4429],{"nctId":4430,"briefTitle":4431,"status":464,"phases":4432,"primaryCompletion":4433,"completion":4434,"start":4435,"enrollment":1789,"conditions":4436,"interventions":4438},"NCT02680392","Functional Outcome and Analgesia in TKA: Radiofrequency vs Continuous Adductor Canal Block",[94],"2017-06-02","2017-07-07","2015-09-14",[4437],"Osteoarthritis, Knee",[4415],{"intervention":4440,"totalTrials":138,"cells":4441},"Sedatives",{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4446,"PHASE3":4448,"PHASE4":4450,"NA":4452},{"trials":4443,"activeCount":102},[],{"trials":4445,"activeCount":102},[],{"trials":4447,"activeCount":102},[],{"trials":4449,"activeCount":102},[],{"trials":4451,"activeCount":102},[],{"trials":4453,"activeCount":102},[4454],{"nctId":4455,"briefTitle":4456,"status":112,"phases":4457,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":1789,"conditions":4460,"interventions":4463},"NCT03345628","Feasibility Study for Neurodevelopment Follow-up Study in PICU",[],"2021-12-30","2018-02-01",[4461,4462],"Bronchiolitis Acute","Pneumonia",[4440],{"intervention":4465,"totalTrials":138,"cells":4466},"Skin biopsy",{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4473,"PHASE4":4475,"NA":4477},{"trials":4468,"activeCount":102},[],{"trials":4470,"activeCount":102},[],{"trials":4472,"activeCount":102},[],{"trials":4474,"activeCount":102},[],{"trials":4476,"activeCount":102},[],{"trials":4478,"activeCount":102},[4479],{"nctId":4480,"briefTitle":4481,"status":464,"phases":4482,"primaryCompletion":4483,"completion":4484,"start":4485,"enrollment":1738,"conditions":4486,"interventions":4487},"NCT02767037","SudoScan as a Biomarker of Parkinson's Disease",[94],"2017-12","2018-06","2016-06",[2024],[4465],{"intervention":4489,"totalTrials":138,"cells":4490},"withdrawal",{"EARLY_PHASE1":4491,"PHASE1":4493,"PHASE2":4495,"PHASE3":4497,"PHASE4":4499,"NA":4501},{"trials":4492,"activeCount":102},[],{"trials":4494,"activeCount":102},[],{"trials":4496,"activeCount":102},[],{"trials":4498,"activeCount":102},[],{"trials":4500,"activeCount":102},[],{"trials":4502,"activeCount":102},[4503],{"nctId":4504,"briefTitle":4505,"status":1077,"phases":4506,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":1055,"conditions":4510,"interventions":4512},"NCT02770443","Withdrawal of Medication in Recovered DCM",[94],"2017-08-24","2019-11","2016-02-19",[4511],"Dilated Cardiomyopathy",[4489,4513],"standard of CARE",{"intervention":4513,"totalTrials":138,"cells":4515},{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4522,"PHASE4":4524,"NA":4526},{"trials":4517,"activeCount":102},[],{"trials":4519,"activeCount":102},[],{"trials":4521,"activeCount":102},[],{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":102},[4528],{"nctId":4504,"briefTitle":4505,"status":1077,"phases":4529,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":1055,"conditions":4530,"interventions":4531},[94],[4511],[4489,4513],{"intervention":4533,"totalTrials":138,"cells":4534},"Long-acting stimulant",{"EARLY_PHASE1":4535,"PHASE1":4537,"PHASE2":4539,"PHASE3":4541,"PHASE4":4543,"NA":4545},{"trials":4536,"activeCount":102},[],{"trials":4538,"activeCount":102},[],{"trials":4540,"activeCount":102},[],{"trials":4542,"activeCount":102},[],{"trials":4544,"activeCount":102},[],{"trials":4546,"activeCount":102},[4547],{"nctId":4548,"briefTitle":4549,"status":112,"phases":4550,"primaryCompletion":4551,"completion":4551,"start":2182,"enrollment":4552,"conditions":4553,"interventions":4555},"NCT02142140","Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)",[94],"2019-02",326,[4554],"Attention Deficit Hyperactivity Disorder (ADHD)",[4533,4533],{"intervention":4557,"totalTrials":138,"cells":4558},"Regular human insulin",{"EARLY_PHASE1":4559,"PHASE1":4561,"PHASE2":4563,"PHASE3":4565,"PHASE4":4567,"NA":4569},{"trials":4560,"activeCount":102},[],{"trials":4562,"activeCount":102},[],{"trials":4564,"activeCount":102},[],{"trials":4566,"activeCount":102},[],{"trials":4568,"activeCount":102},[],{"trials":4570,"activeCount":102},[4571],{"nctId":4572,"briefTitle":4573,"status":112,"phases":4574,"primaryCompletion":2182,"start":4177,"enrollment":969,"conditions":4575,"interventions":4577},"NCT01601561","The Effect of Insulin on Protein Metabolism After Cardiac Surgery",[94],[4576],"Cardiac Surgery",[4557],{"intervention":4579,"totalTrials":138,"cells":4580},"Inderal",{"EARLY_PHASE1":4581,"PHASE1":4583,"PHASE2":4585,"PHASE3":4587,"PHASE4":4589,"NA":4591},{"trials":4582,"activeCount":102},[],{"trials":4584,"activeCount":102},[],{"trials":4586,"activeCount":102},[],{"trials":4588,"activeCount":102},[],{"trials":4590,"activeCount":102},[],{"trials":4592,"activeCount":102},[4593],{"nctId":4594,"briefTitle":4595,"status":112,"phases":4596,"primaryCompletion":1064,"completion":1064,"start":1360,"enrollment":1095,"conditions":4597,"interventions":4599},"NCT01319214","Reducing Drug Craving Memories",[94],[4598],"Cocaine Addiction",[4579],{"intervention":4172,"totalTrials":138,"cells":4601},{"EARLY_PHASE1":4602,"PHASE1":4604,"PHASE2":4606,"PHASE3":4608,"PHASE4":4610,"NA":4612},{"trials":4603,"activeCount":102},[],{"trials":4605,"activeCount":102},[],{"trials":4607,"activeCount":102},[],{"trials":4609,"activeCount":102},[],{"trials":4611,"activeCount":102},[],{"trials":4613,"activeCount":102},[4614],{"nctId":4165,"briefTitle":4166,"status":464,"phases":4615,"primaryCompletion":4168,"completion":4168,"start":4168,"enrollment":1978,"conditions":4616,"interventions":4617},[94],[3482,4170],[4143,4172],{"intervention":4255,"totalTrials":138,"cells":4619},{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4621,"activeCount":102},[],{"trials":4623,"activeCount":102},[],{"trials":4625,"activeCount":102},[],{"trials":4627,"activeCount":102},[],{"trials":4629,"activeCount":102},[],{"trials":4631,"activeCount":102},[4632],{"nctId":4248,"briefTitle":4249,"status":464,"phases":4633,"primaryCompletion":4251,"completion":4251,"start":4252,"enrollment":2944,"conditions":4634,"interventions":4635},[94],[19],[4233,2900,4255],{"intervention":4637,"totalTrials":138,"cells":4638},"Meso-Jet, 2% lidocaine",{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4643,"PHASE3":4645,"PHASE4":4647,"NA":4649},{"trials":4640,"activeCount":102},[],{"trials":4642,"activeCount":102},[],{"trials":4644,"activeCount":102},[],{"trials":4646,"activeCount":102},[],{"trials":4648,"activeCount":102},[],{"trials":4650,"activeCount":102},[4651],{"nctId":4652,"briefTitle":4653,"status":4654,"phases":4655,"primaryCompletion":4656,"completion":4657,"start":4658,"enrollment":969,"conditions":4659,"interventions":4662},"NCT04493528","Needle-free Dental Anesthesia","SUSPENDED",[94],"2023-12-15","2023-12-30","2019-07-18",[4660,4661],"Anesthesia, Local","Needle Phobia",[4637,4663],"Needle,2% lidocaine",{"intervention":4663,"totalTrials":138,"cells":4665},{"EARLY_PHASE1":4666,"PHASE1":4668,"PHASE2":4670,"PHASE3":4672,"PHASE4":4674,"NA":4676},{"trials":4667,"activeCount":102},[],{"trials":4669,"activeCount":102},[],{"trials":4671,"activeCount":102},[],{"trials":4673,"activeCount":102},[],{"trials":4675,"activeCount":102},[],{"trials":4677,"activeCount":102},[4678],{"nctId":4652,"briefTitle":4653,"status":4654,"phases":4679,"primaryCompletion":4656,"completion":4657,"start":4658,"enrollment":969,"conditions":4680,"interventions":4681},[94],[4660,4661],[4637,4663],{"intervention":4683,"totalTrials":138,"cells":4684},"2% Lidocaine",{"EARLY_PHASE1":4685,"PHASE1":4687,"PHASE2":4689,"PHASE3":4691,"PHASE4":4693,"NA":4695},{"trials":4686,"activeCount":102},[],{"trials":4688,"activeCount":102},[],{"trials":4690,"activeCount":102},[],{"trials":4692,"activeCount":102},[],{"trials":4694,"activeCount":102},[],{"trials":4696,"activeCount":102},[4697],{"nctId":4698,"briefTitle":4699,"status":464,"phases":4700,"primaryCompletion":4082,"completion":1570,"start":4701,"enrollment":1217,"conditions":4702,"interventions":4704},"NCT01790464","Glossopharyngeal Nerve Block for Awake Intubation",[94],"2012-04",[4703],"Morbid Obesity",[4683],{"intervention":4706,"totalTrials":138,"cells":4707},"dextrose 10% (D10W ®)",{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4712,"PHASE3":4714,"PHASE4":4716,"NA":4718},{"trials":4709,"activeCount":102},[],{"trials":4711,"activeCount":102},[],{"trials":4713,"activeCount":102},[],{"trials":4715,"activeCount":102},[],{"trials":4717,"activeCount":102},[],{"trials":4719,"activeCount":102},[4720],{"nctId":4721,"briefTitle":4722,"status":464,"phases":4723,"primaryCompletion":4724,"completion":4724,"start":2594,"enrollment":1095,"conditions":4725,"interventions":4727},"NCT00774098","Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections",[94],"2009-09",[4726],"Liver Function",[4706,4728,4729],"hyperinsulinemic normoglycemic clamp","Intravenous normal saline",{"intervention":4728,"totalTrials":138,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4738,"PHASE4":4740,"NA":4742},{"trials":4733,"activeCount":102},[],{"trials":4735,"activeCount":102},[],{"trials":4737,"activeCount":102},[],{"trials":4739,"activeCount":102},[],{"trials":4741,"activeCount":102},[],{"trials":4743,"activeCount":102},[4744],{"nctId":4721,"briefTitle":4722,"status":464,"phases":4745,"primaryCompletion":4724,"completion":4724,"start":2594,"enrollment":1095,"conditions":4746,"interventions":4747},[94],[4726],[4706,4728,4729],{"intervention":4729,"totalTrials":138,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4751,"activeCount":102},[],{"trials":4753,"activeCount":102},[],{"trials":4755,"activeCount":102},[],{"trials":4757,"activeCount":102},[],{"trials":4759,"activeCount":102},[],{"trials":4761,"activeCount":102},[4762],{"nctId":4721,"briefTitle":4722,"status":464,"phases":4763,"primaryCompletion":4724,"completion":4724,"start":2594,"enrollment":1095,"conditions":4764,"interventions":4765},[94],[4726],[4706,4728,4729],{"intervention":4767,"totalTrials":138,"cells":4768},"Radioactive Tracers",{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4770,"activeCount":102},[],{"trials":4772,"activeCount":102},[],{"trials":4774,"activeCount":102},[],{"trials":4776,"activeCount":102},[],{"trials":4778,"activeCount":102},[],{"trials":4780,"activeCount":102},[4781],{"nctId":4782,"briefTitle":4783,"status":112,"phases":4784,"primaryCompletion":4785,"completion":4786,"start":4787,"enrollment":1789,"conditions":4788,"interventions":4792},"NCT03049345","Gastric Cancer Sentinel Lymph Node Mapping",[94],"2022-06-30","2022-09-30","2016-07-01",[4789,4790,4791],"Gastric Cancer","Sentinel Lymph Node","Early Gastric Cancer",[4767,4793],"Methylene Blue 20 MG\u002FML",{"intervention":4793,"totalTrials":138,"cells":4795},{"EARLY_PHASE1":4796,"PHASE1":4798,"PHASE2":4800,"PHASE3":4802,"PHASE4":4804,"NA":4806},{"trials":4797,"activeCount":102},[],{"trials":4799,"activeCount":102},[],{"trials":4801,"activeCount":102},[],{"trials":4803,"activeCount":102},[],{"trials":4805,"activeCount":102},[],{"trials":4807,"activeCount":102},[4808],{"nctId":4782,"briefTitle":4783,"status":112,"phases":4809,"primaryCompletion":4785,"completion":4786,"start":4787,"enrollment":1789,"conditions":4810,"interventions":4811},[94],[4789,4790,4791],[4767,4793],{"intervention":4813,"totalTrials":138,"cells":4814},"Long-acting bronchodilator therapy",{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4819,"PHASE3":4821,"PHASE4":4823,"NA":4825},{"trials":4816,"activeCount":102},[],{"trials":4818,"activeCount":102},[],{"trials":4820,"activeCount":102},[],{"trials":4822,"activeCount":102},[],{"trials":4824,"activeCount":102},[],{"trials":4826,"activeCount":102},[4827],{"nctId":4828,"briefTitle":4829,"status":464,"phases":4830,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":1906,"conditions":4834,"interventions":4836},"NCT06495047","Assessing Optimal Inhaler Strategies During Acute Exacerbations of COPD (AECOPDs) Using Oscillometry",[],"2025-06-30","2025-07-31","2025-06-01",[1908,4835],"COPD Exacerbation Acute",[4813,4837],"Short-acting bronchodilator therapy",{"intervention":4837,"totalTrials":138,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4844,"PHASE3":4846,"PHASE4":4848,"NA":4850},{"trials":4841,"activeCount":102},[],{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[],{"trials":4849,"activeCount":102},[],{"trials":4851,"activeCount":102},[4852],{"nctId":4828,"briefTitle":4829,"status":464,"phases":4853,"primaryCompletion":4831,"completion":4832,"start":4833,"enrollment":1906,"conditions":4854,"interventions":4855},[],[1908,4835],[4813,4837],{"intervention":4857,"totalTrials":138,"cells":4858},"Tibolone 2.5 Mg Oral",{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4863,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4860,"activeCount":102},[],{"trials":4862,"activeCount":102},[],{"trials":4864,"activeCount":102},[],{"trials":4866,"activeCount":102},[],{"trials":4868,"activeCount":102},[],{"trials":4870,"activeCount":102},[4871],{"nctId":4872,"briefTitle":4873,"status":2258,"phases":4874,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":102,"conditions":4877,"interventions":4880},"NCT05568940","Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids",[],"2026-04","2024-09",[4878,4879],"Endometriosis","Fibroids",[4857],{"intervention":4882,"totalTrials":138,"cells":4883},"Methylphenidate compounds and \u002For Amphetamine compounds and\u002For Strattera or Guanfacine",{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4890,"PHASE4":4892,"NA":4894},{"trials":4885,"activeCount":102},[],{"trials":4887,"activeCount":102},[],{"trials":4889,"activeCount":102},[],{"trials":4891,"activeCount":102},[],{"trials":4893,"activeCount":102},[],{"trials":4895,"activeCount":102},[4896],{"nctId":4897,"briefTitle":4898,"status":112,"phases":4899,"primaryCompletion":2047,"completion":2047,"start":2167,"enrollment":1304,"conditions":4900,"interventions":4901},"NCT02788851","The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)",[94],[4554],[4882],{"intervention":4903,"totalTrials":138,"cells":4904},"Teriflunomide",{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4909,"PHASE3":4911,"PHASE4":4913,"NA":4915},{"trials":4906,"activeCount":102},[],{"trials":4908,"activeCount":102},[],{"trials":4910,"activeCount":102},[],{"trials":4912,"activeCount":102},[],{"trials":4914,"activeCount":102},[],{"trials":4916,"activeCount":102},[4917],{"nctId":4918,"briefTitle":4919,"status":464,"phases":4920,"primaryCompletion":3359,"completion":3359,"start":1623,"enrollment":1217,"conditions":4921,"interventions":4923},"NCT03561402","Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)",[],[4922],"Multiple Sclerosis, Relapsing-Remitting",[4903],{"intervention":4925,"totalTrials":138,"cells":4926},"epidural fentanyl",{"EARLY_PHASE1":4927,"PHASE1":4929,"PHASE2":4931,"PHASE3":4933,"PHASE4":4935,"NA":4937},{"trials":4928,"activeCount":102},[],{"trials":4930,"activeCount":102},[],{"trials":4932,"activeCount":102},[],{"trials":4934,"activeCount":102},[],{"trials":4936,"activeCount":102},[],{"trials":4938,"activeCount":102},[4939],{"nctId":4940,"briefTitle":4941,"status":112,"phases":4942,"primaryCompletion":4943,"completion":4129,"start":4337,"enrollment":969,"conditions":4944,"interventions":4946},"NCT01646775","The Effect of Epidural Fentanyl on Immune Function",[94],"2014-10",[4945],"Malignancy",[4925],{"intervention":4948,"totalTrials":138,"cells":4949},"Gilenya",{"EARLY_PHASE1":4950,"PHASE1":4952,"PHASE2":4954,"PHASE3":4956,"PHASE4":4958,"NA":4960},{"trials":4951,"activeCount":102},[],{"trials":4953,"activeCount":102},[],{"trials":4955,"activeCount":102},[],{"trials":4957,"activeCount":102},[],{"trials":4959,"activeCount":102},[],{"trials":4961,"activeCount":102},[4962],{"nctId":4963,"briefTitle":4964,"status":464,"phases":4965,"primaryCompletion":4966,"completion":4967,"start":4968,"enrollment":4969,"conditions":4970,"interventions":4972},"NCT02137707","Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya",[],"2017-11","2018-10-30","2012-11",135,[4971],"Multiple Sclerosis-Relapsing-Remitting",[4948],{"intervention":4182,"totalTrials":138,"cells":4974},{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4985},{"trials":4976,"activeCount":102},[],{"trials":4978,"activeCount":102},[],{"trials":4980,"activeCount":102},[],{"trials":4982,"activeCount":102},[],{"trials":4984,"activeCount":102},[],{"trials":4986,"activeCount":102},[4987],{"nctId":4174,"briefTitle":4175,"status":464,"phases":4988,"primaryCompletion":4177,"completion":4178,"start":4179,"enrollment":1095,"conditions":4989,"interventions":4990},[94],[3702,3703,3704],[4143,4182],{"intervention":4992,"totalTrials":138,"cells":4993},"Atorvastatin; Fenofibrate; Niacin",{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4995,"activeCount":102},[],{"trials":4997,"activeCount":102},[],{"trials":4999,"activeCount":102},[],{"trials":5001,"activeCount":102},[],{"trials":5003,"activeCount":102},[],{"trials":5005,"activeCount":102},[5006],{"nctId":5007,"briefTitle":5008,"status":464,"phases":5009,"primaryCompletion":2495,"completion":2495,"start":5010,"enrollment":3103,"conditions":5011,"interventions":5015},"NCT00458055","High-Density Lipoprotein (HDL) Treatment Study",[94],"2006-11",[5012,5013,5014],"Coronary Arteriosclerosis","Hypoalphalipoproteinemias","Genetic Diseases, Inborn",[4992],{"intervention":5017,"totalTrials":138,"cells":5018},"Amitriptyline Hydrochloride",{"EARLY_PHASE1":5019,"PHASE1":5021,"PHASE2":5023,"PHASE3":5025,"PHASE4":5027,"NA":5029},{"trials":5020,"activeCount":102},[],{"trials":5022,"activeCount":102},[],{"trials":5024,"activeCount":102},[],{"trials":5026,"activeCount":102},[],{"trials":5028,"activeCount":102},[],{"trials":5030,"activeCount":102},[5031],{"nctId":5032,"briefTitle":5033,"status":464,"phases":5034,"completion":3456,"start":5035,"enrollment":5036,"conditions":5037,"interventions":5040},"NCT00381199","Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia",[94],"2006-04",32,[5038,5039],"Fibromyalgia","Sleep Initiation and Maintenance Disorders",[5017,5041],"Nabilone",{"intervention":5041,"totalTrials":138,"cells":5043},{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5048,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5045,"activeCount":102},[],{"trials":5047,"activeCount":102},[],{"trials":5049,"activeCount":102},[],{"trials":5051,"activeCount":102},[],{"trials":5053,"activeCount":102},[],{"trials":5055,"activeCount":102},[5056],{"nctId":5032,"briefTitle":5033,"status":464,"phases":5057,"completion":3456,"start":5035,"enrollment":5036,"conditions":5058,"interventions":5059},[94],[5038,5039],[5017,5041],{"intervention":5061,"totalTrials":138,"cells":5062},"Flumist®",{"EARLY_PHASE1":5063,"PHASE1":5065,"PHASE2":5067,"PHASE3":5069,"PHASE4":5071,"NA":5073},{"trials":5064,"activeCount":102},[],{"trials":5066,"activeCount":102},[],{"trials":5068,"activeCount":102},[],{"trials":5070,"activeCount":102},[],{"trials":5072,"activeCount":102},[],{"trials":5074,"activeCount":102},[5075],{"nctId":5076,"briefTitle":5077,"status":112,"phases":5078,"primaryCompletion":1570,"completion":5079,"start":3051,"enrollment":480,"conditions":5080,"interventions":5082},"NCT01885169","LAIV (Flumist®) Administration in CF Patients",[],"2015-12",[5081],"Cystic Fibrosis",[5061],{"intervention":4193,"totalTrials":138,"cells":5084},{"EARLY_PHASE1":5085,"PHASE1":5087,"PHASE2":5089,"PHASE3":5091,"PHASE4":5093,"NA":5095},{"trials":5086,"activeCount":102},[],{"trials":5088,"activeCount":102},[],{"trials":5090,"activeCount":102},[],{"trials":5092,"activeCount":102},[],{"trials":5094,"activeCount":102},[],{"trials":5096,"activeCount":102},[5097],{"nctId":4184,"briefTitle":4185,"status":112,"phases":5098,"primaryCompletion":4187,"completion":4187,"start":4188,"enrollment":2307,"conditions":5099,"interventions":5100},[94],[4190,4191],[4143,4193],{"intervention":5102,"totalTrials":138,"cells":5103},"Regular insulin",{"EARLY_PHASE1":5104,"PHASE1":5106,"PHASE2":5108,"PHASE3":5110,"PHASE4":5112,"NA":5114},{"trials":5105,"activeCount":102},[],{"trials":5107,"activeCount":102},[],{"trials":5109,"activeCount":102},[],{"trials":5111,"activeCount":102},[],{"trials":5113,"activeCount":102},[],{"trials":5115,"activeCount":102},[5116],{"nctId":5117,"briefTitle":5118,"status":112,"phases":5119,"primaryCompletion":5120,"completion":5120,"start":5121,"enrollment":5122,"conditions":5123,"interventions":5126},"NCT03324867","The Effect of Intranasal Insulin Administration on Cognitive Function After Cardiac Surgery.",[94],"2023-04","2022-04",316,[5124,5125,119],"Cognitive Decline","Heart Diseases",[5102,5127],"Normal Saline Flush, 0.9% Injectable Solution",{"intervention":5127,"totalTrials":138,"cells":5129},{"EARLY_PHASE1":5130,"PHASE1":5132,"PHASE2":5134,"PHASE3":5136,"PHASE4":5138,"NA":5140},{"trials":5131,"activeCount":102},[],{"trials":5133,"activeCount":102},[],{"trials":5135,"activeCount":102},[],{"trials":5137,"activeCount":102},[],{"trials":5139,"activeCount":102},[],{"trials":5141,"activeCount":102},[5142],{"nctId":5117,"briefTitle":5118,"status":112,"phases":5143,"primaryCompletion":5120,"completion":5120,"start":5121,"enrollment":5122,"conditions":5144,"interventions":5145},[94],[5124,5125,119],[5102,5127],{"intervention":5147,"totalTrials":138,"cells":5148},"Vitamin D3",{"EARLY_PHASE1":5149,"PHASE1":5151,"PHASE2":5153,"PHASE3":5155,"PHASE4":5157,"NA":5159},{"trials":5150,"activeCount":102},[],{"trials":5152,"activeCount":102},[],{"trials":5154,"activeCount":102},[],{"trials":5156,"activeCount":102},[],{"trials":5158,"activeCount":102},[],{"trials":5160,"activeCount":102},[5161],{"nctId":5162,"briefTitle":5163,"status":1077,"phases":5164,"primaryCompletion":5165,"completion":5165,"start":3900,"enrollment":26,"conditions":5166,"interventions":5168},"NCT01349764","Effect of Vitamin D Replacement in Patients With Urolithiasis",[],"2016-05",[5167],"Urolithiasis",[5147],{"intervention":5170,"totalTrials":138,"cells":5171},"Fiasp+Pramlintide Closed-Loop System",{"EARLY_PHASE1":5172,"PHASE1":5174,"PHASE2":5176,"PHASE3":5178,"PHASE4":5180,"NA":5182},{"trials":5173,"activeCount":102},[],{"trials":5175,"activeCount":102},[],{"trials":5177,"activeCount":102},[],{"trials":5179,"activeCount":102},[],{"trials":5181,"activeCount":102},[],{"trials":5183,"activeCount":102},[5184],{"nctId":5185,"briefTitle":5186,"status":464,"phases":5187,"primaryCompletion":5188,"completion":5188,"start":5189,"enrollment":29,"conditions":5190,"interventions":5191},"NCT03993366","Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement",[94],"2019-08-06","2019-03-01",[683],[5170],{"intervention":5193,"totalTrials":138,"cells":5194},"lidocaine, bupivacaine, epinephrine, dexamethasone",{"EARLY_PHASE1":5195,"PHASE1":5197,"PHASE2":5199,"PHASE3":5201,"PHASE4":5203,"NA":5205},{"trials":5196,"activeCount":102},[],{"trials":5198,"activeCount":102},[],{"trials":5200,"activeCount":102},[],{"trials":5202,"activeCount":102},[],{"trials":5204,"activeCount":102},[],{"trials":5206,"activeCount":102},[5207],{"nctId":5208,"briefTitle":5209,"status":112,"phases":5210,"primaryCompletion":2047,"completion":2047,"start":5211,"enrollment":5212,"conditions":5213,"interventions":5215},"NCT03595514","Single Versus Double Injection Costoclavicular Block",[94],"2018-07-30",90,[5214],"Upper Extremity Injury",[5193],{"intervention":5217,"totalTrials":138,"cells":5218},"Esmolol",{"EARLY_PHASE1":5219,"PHASE1":5221,"PHASE2":5223,"PHASE3":5225,"PHASE4":5227,"NA":5229},{"trials":5220,"activeCount":102},[],{"trials":5222,"activeCount":102},[],{"trials":5224,"activeCount":102},[],{"trials":5226,"activeCount":102},[],{"trials":5228,"activeCount":102},[],{"trials":5230,"activeCount":102},[5231],{"nctId":5232,"briefTitle":5233,"status":464,"phases":5234,"primaryCompletion":3312,"completion":1904,"start":1813,"enrollment":1789,"conditions":5235,"interventions":5236},"NCT01275911","Non-opioid Analgesia for Fast-track Surgery",[94],[1391],[5217,5237],"Remifentanil",{"intervention":5237,"totalTrials":138,"cells":5239},{"EARLY_PHASE1":5240,"PHASE1":5242,"PHASE2":5244,"PHASE3":5246,"PHASE4":5248,"NA":5250},{"trials":5241,"activeCount":102},[],{"trials":5243,"activeCount":102},[],{"trials":5245,"activeCount":102},[],{"trials":5247,"activeCount":102},[],{"trials":5249,"activeCount":102},[],{"trials":5251,"activeCount":102},[5252],{"nctId":5232,"briefTitle":5233,"status":464,"phases":5253,"primaryCompletion":3312,"completion":1904,"start":1813,"enrollment":1789,"conditions":5254,"interventions":5255},[94],[1391],[5217,5237],{"intervention":5257,"totalTrials":138,"cells":5258},"TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and\u002For surgery.",{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5263,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5260,"activeCount":102},[],{"trials":5262,"activeCount":102},[],{"trials":5264,"activeCount":102},[],{"trials":5266,"activeCount":102},[],{"trials":5268,"activeCount":102},[],{"trials":5270,"activeCount":102},[5271],{"nctId":5272,"briefTitle":5273,"status":464,"phases":5274,"primaryCompletion":3947,"completion":3947,"start":1570,"enrollment":1240,"conditions":5275,"interventions":5277},"NCT02135627","TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL.",[94],[5276],"MALIGNANT GASTROINTESTINAL BLEEDING",[5257],{"intervention":5279,"totalTrials":138,"cells":5280},"Fluid challenge",{"EARLY_PHASE1":5281,"PHASE1":5283,"PHASE2":5285,"PHASE3":5287,"PHASE4":5289,"NA":5291},{"trials":5282,"activeCount":102},[],{"trials":5284,"activeCount":102},[],{"trials":5286,"activeCount":102},[],{"trials":5288,"activeCount":102},[],{"trials":5290,"activeCount":102},[],{"trials":5292,"activeCount":102},[5293],{"nctId":5294,"briefTitle":5295,"status":112,"phases":5296,"primaryCompletion":2115,"completion":449,"start":2943,"enrollment":5297,"conditions":5298,"interventions":5300},"NCT02418663","Fluid Responsiveness in the Postoperative Patient: a Prospective Study",[94],245,[5299],"Actual Impaired Fluid Volume",[5279],{"intervention":4367,"totalTrials":138,"cells":5302},{"EARLY_PHASE1":5303,"PHASE1":5305,"PHASE2":5307,"PHASE3":5309,"PHASE4":5311,"NA":5313},{"trials":5304,"activeCount":102},[],{"trials":5306,"activeCount":102},[],{"trials":5308,"activeCount":102},[],{"trials":5310,"activeCount":102},[],{"trials":5312,"activeCount":102},[],{"trials":5314,"activeCount":102},[5315],{"nctId":4360,"briefTitle":4361,"status":112,"phases":5316,"primaryCompletion":4211,"completion":4211,"start":4363,"enrollment":655,"conditions":5317,"interventions":5318},[94],[22,19,4365],[4367,4265],{"intervention":5320,"totalTrials":138,"cells":5321},"Albumin",{"EARLY_PHASE1":5322,"PHASE1":5324,"PHASE2":5326,"PHASE3":5328,"PHASE4":5330,"NA":5332},{"trials":5323,"activeCount":102},[],{"trials":5325,"activeCount":102},[],{"trials":5327,"activeCount":102},[],{"trials":5329,"activeCount":102},[],{"trials":5331,"activeCount":102},[],{"trials":5333,"activeCount":102},[5334],{"nctId":5335,"briefTitle":5336,"status":112,"phases":5337,"primaryCompletion":3383,"completion":3383,"start":1348,"enrollment":494,"conditions":5338,"interventions":5340},"NCT00842803","Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant",[94],[5339],"Liver Transplantation",[5320],{"intervention":5342,"totalTrials":138,"cells":5343},"Nintedanib 150 milligrams [Ofev]",{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5348,"PHASE3":5350,"PHASE4":5352,"NA":5354},{"trials":5345,"activeCount":102},[],{"trials":5347,"activeCount":102},[],{"trials":5349,"activeCount":102},[],{"trials":5351,"activeCount":102},[],{"trials":5353,"activeCount":102},[],{"trials":5355,"activeCount":102},[5356],{"nctId":5357,"briefTitle":5358,"status":1077,"phases":5359,"primaryCompletion":535,"completion":5360,"start":5361,"enrollment":5362,"conditions":5363,"interventions":5366},"NCT05335278","Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease",[94],"2025-04-30","2021-06-01",11,[5364,5365],"Interstitial Lung Disease","Myopathy, Inflammatory",[5342],{"intervention":5368,"totalTrials":138,"cells":5369},"Biosimilar",{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5378,"NA":5380},{"trials":5371,"activeCount":102},[],{"trials":5373,"activeCount":102},[],{"trials":5375,"activeCount":102},[],{"trials":5377,"activeCount":102},[],{"trials":5379,"activeCount":102},[],{"trials":5381,"activeCount":102},[5382],{"nctId":5383,"briefTitle":5384,"status":112,"phases":5385,"primaryCompletion":5386,"completion":5387,"start":5388,"enrollment":5389,"conditions":5390,"interventions":5393},"NCT03729674","Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs",[],"2021-03-30","2022-12-31","2018-11-26",800,[2051,5391,5392,2499],"Ankylosing Spondylitis","Ulcerative Colitis",[5368,5394],"Originator (legacy) drug",{"intervention":5394,"totalTrials":138,"cells":5396},{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5403,"PHASE4":5405,"NA":5407},{"trials":5398,"activeCount":102},[],{"trials":5400,"activeCount":102},[],{"trials":5402,"activeCount":102},[],{"trials":5404,"activeCount":102},[],{"trials":5406,"activeCount":102},[],{"trials":5408,"activeCount":102},[5409],{"nctId":5383,"briefTitle":5384,"status":112,"phases":5410,"primaryCompletion":5386,"completion":5387,"start":5388,"enrollment":5389,"conditions":5411,"interventions":5412},[],[2051,5391,5392,2499],[5368,5394],{"intervention":5414,"totalTrials":138,"cells":5415},"Besifloxacin",{"EARLY_PHASE1":5416,"PHASE1":5418,"PHASE2":5420,"PHASE3":5422,"PHASE4":5424,"NA":5426},{"trials":5417,"activeCount":102},[],{"trials":5419,"activeCount":102},[],{"trials":5421,"activeCount":102},[],{"trials":5423,"activeCount":102},[],{"trials":5425,"activeCount":102},[],{"trials":5427,"activeCount":102},[5428],{"nctId":5429,"briefTitle":5430,"status":464,"phases":5431,"primaryCompletion":5432,"completion":1621,"start":5433,"enrollment":5036,"conditions":5434,"interventions":5436},"NCT02497365","Besifloxacin in Bacterial Keratitis",[94],"2019-06","2015-09",[5435],"Bacterial Keratitis",[5414,5437],"Tobramycin and Cefazolin",{"intervention":5437,"totalTrials":138,"cells":5439},{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5446,"PHASE4":5448,"NA":5450},{"trials":5441,"activeCount":102},[],{"trials":5443,"activeCount":102},[],{"trials":5445,"activeCount":102},[],{"trials":5447,"activeCount":102},[],{"trials":5449,"activeCount":102},[],{"trials":5451,"activeCount":102},[5452],{"nctId":5429,"briefTitle":5430,"status":464,"phases":5453,"primaryCompletion":5432,"completion":1621,"start":5433,"enrollment":5036,"conditions":5454,"interventions":5455},[94],[5435],[5414,5437],{"intervention":5457,"totalTrials":138,"cells":5458},"Sugammadex",{"EARLY_PHASE1":5459,"PHASE1":5461,"PHASE2":5463,"PHASE3":5465,"PHASE4":5467,"NA":5469},{"trials":5460,"activeCount":102},[],{"trials":5462,"activeCount":102},[],{"trials":5464,"activeCount":102},[],{"trials":5466,"activeCount":102},[],{"trials":5468,"activeCount":102},[],{"trials":5470,"activeCount":102},[5471],{"nctId":5472,"briefTitle":5473,"status":112,"phases":5474,"primaryCompletion":5475,"completion":5476,"start":5477,"enrollment":12,"conditions":5478,"interventions":5480},"NCT03791801","The Use of Sugammadex in the Critically Ill",[94],"2020-12-01","2021-07-01","2019-09-01",[5479],"Critical Illness",[5457,5481,5482,5483],"Neostigmine","Rocuronium","Glycopyrrolate",{"intervention":5481,"totalTrials":138,"cells":5485},{"EARLY_PHASE1":5486,"PHASE1":5488,"PHASE2":5490,"PHASE3":5492,"PHASE4":5494,"NA":5496},{"trials":5487,"activeCount":102},[],{"trials":5489,"activeCount":102},[],{"trials":5491,"activeCount":102},[],{"trials":5493,"activeCount":102},[],{"trials":5495,"activeCount":102},[],{"trials":5497,"activeCount":102},[5498],{"nctId":5472,"briefTitle":5473,"status":112,"phases":5499,"primaryCompletion":5475,"completion":5476,"start":5477,"enrollment":12,"conditions":5500,"interventions":5501},[94],[5479],[5457,5481,5482,5483],{"intervention":5482,"totalTrials":138,"cells":5503},{"EARLY_PHASE1":5504,"PHASE1":5506,"PHASE2":5508,"PHASE3":5510,"PHASE4":5512,"NA":5514},{"trials":5505,"activeCount":102},[],{"trials":5507,"activeCount":102},[],{"trials":5509,"activeCount":102},[],{"trials":5511,"activeCount":102},[],{"trials":5513,"activeCount":102},[],{"trials":5515,"activeCount":102},[5516],{"nctId":5472,"briefTitle":5473,"status":112,"phases":5517,"primaryCompletion":5475,"completion":5476,"start":5477,"enrollment":12,"conditions":5518,"interventions":5519},[94],[5479],[5457,5481,5482,5483],{"intervention":5483,"totalTrials":138,"cells":5521},{"EARLY_PHASE1":5522,"PHASE1":5524,"PHASE2":5526,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5523,"activeCount":102},[],{"trials":5525,"activeCount":102},[],{"trials":5527,"activeCount":102},[],{"trials":5529,"activeCount":102},[],{"trials":5531,"activeCount":102},[],{"trials":5533,"activeCount":102},[5534],{"nctId":5472,"briefTitle":5473,"status":112,"phases":5535,"primaryCompletion":5475,"completion":5476,"start":5477,"enrollment":12,"conditions":5536,"interventions":5537},[94],[5479],[5457,5481,5482,5483]]